STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 201276

TO: Sarvamangala Devi **Art Unit: 1645** **Location: REM-3C18** **Case Serial Number: 10/749143** **Friday, September 22, 2006**	**From: Beverly Shears** **Location: Biotech-Chem Library** **REM-1A54** **Phone: (571)272-2528** **beverly.shears@uspto.gov**

Search Notes

— 4-480 201276 LB

STIC-Biotech/ChemLib CRFB

From: Devi, Sarvamangala
Sent: 74495 Tuesday, September 12, 2006 8:07 AM
To: STIC-Biotech/ChemLib
Cc: Shears, Beverly
Subject: 10/749,143

Please ask **Ms. Beverly Shears** to perform this search.

In application 10/749,143, please perform a text search for the following claims:

Claim 1. An isolated polypeptide or protein of *Neisseria meningitidis* (meningococc?) having a molecular weight of about 40 kD to about 55 kD as determined in SDS polyacrylamide gel electrophoresis (SDS PAGE).

Claim 2. An isolated polypeptide or protein of *Neisseria meningitidis* (meningococc?) having a molecular weight of 40 ± 10 kD to about 55 ± 10 kD as determined in SDS polyacrylamide gel electrophoresis (SDS PAGE).

Claim 3. The polypeptide or protein of claim 1 which has a molecular weight of about 44 to 53 kD.

Claim 4. The polypeptide or protein of claim 2 which has a molecular weight of 44 ± 10 kD to about 53 ± 10 kD.

Thanks.

S. DEVI, Ph.D.
Primary Examiner
AU 1645
Rems - 3C18

****
Searcher:_____
Searcher Phone:_____
Date Searcher Picked up:_____
Date completed:_____
Searcher Prep Time:_____
Online Time:_____

****
Type of Search
NA#_____ AA#:_____
S/L:_____ Oligomer:_____
Encode/Transl:_____
Structure #:_____Text:____
Inventor:_____ Litigation:___

****
Vendors and cost where applicable
STN:_____
DIALOG:_____
QUESTEL/ORBIT:_____
LEXIS/NEXIS:_____
SEQUENCE SYSTEM:_____
WWW/Internet:_____
Other (Specify):_____

Date completed: _____
Searcher: Beverly e2528
Terminal time: _____
Elapsed time: _____
CPU time:_____
Total time: _____
Number of Searches: _____
Number of Databases: _____

Search Site
_____ STIC
_____ CM-1
_____ Pre-S

Type of Search
_____ N.A. Sequence
_____ A.A. Sequence
_____ Structure
_____ Bibliographic

Vendors
_____ IG
_____ ✓ STN
_____ ✓ Dialog
_____ APS
_____ Geninfo
_____ SDC
_____ DARC/Questel
_____ Other

PTO-1590 (9-90)

22sep06 10:34:20 User219783 Session D2226.2

SYSTEM:OS - DIALOG OneSearch
File 65:Inside Conferences 1993-2006/Sep 22
(c) 2006 BLDSC all rts. reserv.
File 266:FEDRIP 2006/Aug
Comp & dist by NTIS, Intl Copyright All Rights Res
File 440:Current Contents Search(R) 1990-2006/Sep 22
(c) 2006 The Thomson Corp
File 348:EUROPEAN PATENTS 1978-2006/ 200638
(c) 2006 European Patent Office
*File 348: For important information about IPCR/8 and forthcoming changes to the IC= index, see HELP NEWSIPCR.
File 357:Derwent Biotech Res. _1982-2006/Sep W3
(c) 2006 The Thomson Corp.
File 113:European R&D Database 1997
(c)1997 Reed-Elsevier(UK)Ltd All rts reserv
*File 113: This file is closed (no updates)

Set Items Description
--- ----- -----------

- key terms

Set Items Description
S1 19966 ((NA OR SODIUM)(W)DODECYL OR SDS)(5W)(PAGE OR (POLYACRYL? - OR POLY(W)ACRYL))(3W)ELECTROPHOR?
S2 82000 GEL(W)ELECTROPHOR?

S5 493 ((MENINGITID? OR MENINGOCOCC?)(S)(POLYPROTEIN? ? OR PROTEIN? ? OR PEPTIDE? ? OR POLYPEPTIDE? ?))(S)(ISOLATING OR ISOLATE? ? OR ISOL?? OR RECOVER?)
S6 43 (S1 OR S2) AND S5
S7 42 RD (unique items)
>>>No matching display code(s) found in file(s): 65, 113

7/3,AB/1 (Item 1 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2006 The Thomson Corp. All rts. reserv.

20243162 Document Delivery Available: 000227045600048 References: 36
TITLE: Stability of PorA during a meningococcal disease epidemic
AUTHOR(S): Devoy AF; Dyet KH; Martin DR (REPRINT)
AUTHOR(S) E-MAIL: diana.martin@esr.cri.nz
CORPORATE SOURCE: Inst Environm Sci & Res, Communicable Dis Grp, POB 50348/Porirua//New Zealand/ (REPRINT); Inst Environm Sci & Res, Communicable Dis Grp, /Porirua//New Zealand/
PUBLICATION TYPE: JOURNAL
PUBLICATION: JOURNAL OF CLINICAL MICROBIOLOGY, 2005, V43, N2 (FEB), P 832-837
GENUINE ARTICLE#: 897ZO
PUBLISHER: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
ISSN: 0095-1137
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: **Meningococci** causing New Zealand's epidemic, which began in 1991, are defined as group B, serosubtype P1.4 (subtype P1.7-2,4), belonging to the ST-41/ST-44 complex, lineage III. Of the 2,358 group B **isolates** obtained from disease cases from 1991 through 2003, 85.7% (2,021 of 2,358) were determined to be serosubtype PIA. Of the remaining **isolates**, 156 (6.6%) were not serosubtypeable (NST). Molecular

analysis of the porA gene from these B:NST **meningococcal isolates** was used to determine the reason. Most NST **isolates** (156, 88.5%) expressed a PorA that was distinct from P1.7-2,4 PorA. Fifteen **isolates** expressed variants of PI.7-2,4 PorA, and a further three expressed P1.7-2,4 PorA without any sequence variation. These three **isolates** expressed P1.7-2,4 PorA at very low levels, as determined by **sodium dodecyl** sulfate-**polyacrylamide gel electrophoresis** analysis, and showed variation in the porA promoter region. Among the 15 **meningococcal isolates** expressing variants of PI.7-2,4 PorA, 11 different sequence variations were found. Compared with the P1.7-2,4 PorA sequence, the sequences of these variants contained deletions, insertions, or single-nucleotide substitutions in the VR2 region of the **protein**. Multilocus restriction typing was used to assess the clonal derivations of B:NST case **isolates**. **Meningococcal isolates** expressing distinct PorA **proteins** belonged mostly to clonal types that were unrelated to the epidemic strain, whereas all **meningococcal isolates** expressing variants of PI.7-2,4 PorA belonged to the ST-41/ST-44 complex, lineage III. These results, together with those obtained serologically, demonstrate that the P1.7-2,4 PorA **protein** of **meningococci** responsible for New Zealand's epidemic has remained relatively stable over 13 years and support the use of a strain-specific outer membrane vesicle vaccine to control the epidemic.

7/3,AB/2 (Item 2 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

19494088 Document Delivery Available: 000224487500006 References: 52
TITLE: Proteome analysis of Neisseria meningitidis serogroup A
AUTHOR(S): Bernardini G; Renzone G; Comanducci M; Mini R; Arena S; D'Ambrosio C; Bambini S; Trabalzini L; Grandi G; Martelli P; Achtman M; Scaloni A; Ratti G; Santucci A (REPRINT)
AUTHOR(S) E-MAIL: santucci@unisi.it
CORPORATE SOURCE: Univ Siena, Dipartimento Biol Mol, Via Florentina 1/I-53100 Siena//Italy/ (REPRINT); Univ Siena, Dipartimento Biol Mol, /I-53100 Siena//Italy/; CNR, Proteom & Mass Spectrometry Lab, /Naples//Italy/; IRIS Res Ctr, Chiron Vaccines, /Siena//Italy/; Max Planck Inst Infektionsbiol, /Berlin//Germany/
PUBLICATION TYPE: JOURNAL
PUBLICATION: PROTEOMICS, 2004, V4, N10 (OCT), P2893-2926
GENUINE ARTICLE#: 862JS
PUBLISHER: WILEY-V C H VERLAG GMBH, PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
ISSN: 1615-9853
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: Neisseria **meningitidis** is an encapsulated Gram-negative bacterium responsible for significant morbidity and mortality worldwide. **Meningococci** are opportunistic pathogens, carried in the nasopharynx of approximately 10% of asymptomatic adults. Occasionally they enter the bloodstream to cause septicaemia and meningitis. **Meningococci** are classified into serogroups on the basis of polysaccharide capsule diversity, and serogroup A strains have caused major epidemics mainly in the developing world. Here we describe a two-dimensional **gel electrophoresis protein** map of the serogroup A strain Z4970, a clinical **isolate** classified as ancestral to several pandemic waves. To our knowledge this is the first systematically annotated proteomic map for N. **meningitidis**. Total **protein** samples from bacteria grown on GC-agar were electrophoretically separated and **protein** species

were identified by matrix-assisted laser desorption/ionization time of flight spectrometry. We identified the products of 273 genes, covering several functional classes, including 94 **proteins** so far considered as hypothetical. We also describe several **protein** species encoded by genes reported by DNA microarray studies as being regulated in physiological conditions which are relevant to natural **meningococcal** pathogenicity. Since menA differs from other serogroups by having a fairly stable clonal population structure (i.e. with a low degree of variability), we envisaged comparative mapping as a useful tool for microevolution studies, in conjunction with established genotyping methods. As a proof of principle, we performed a comparative analysis on the B subunit of the **meningococcal** transferrin receptor, a vaccine candidate encoded by the tbpB gene, and a known marker of population diversity in **meningococci**. The results show that TbpB spot pattern variation observed in the maps of nine clinical **isolates** from diverse epidemic spreads, fits previous analyses based on allelic variations of the tbpB gene.

7/3,AB/3 (Item 3 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

18167534 Document Delivery Available: 000220481600008 References: 24
TITLE: GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence
AUTHOR(S): Adu-Bobie J; Lupetti P; Brunelli B; Granoff D; Norais N; Ferrari G; Grandi G; Rappuoli R (REPRINT); Pizza M
AUTHOR(S) E-MAIL: rino rappuoli@chiron.com
CORPORATE SOURCE: Univ Siena, IRIS, Foirentina 1/I-53100 Siena//Italy/ (REPRINT); Univ Siena, IRIS, /I-53100 Siena//Italy/; Univ Siena, Dipartimento Biol Evolut, /I-53100 Siena//Italy/; Childrens Hosp, Oakland Res Inst, /Oakland//CA/94609
PUBLICATION TYPE: JOURNAL
PUBLICATION: INFECTION AND IMMUNITY, 2004, V72, N4 (APR), P1914-1919
GENUINE ARTICLE#: 807DG
PUBLISHER: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
ISSN: 0019-9567
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: GNA33 is a membrane-bound lipoprotein with murein hydrolase activity that is present in all Neisseria species and well conserved in different **meningococcal isolates**. The **protein** shows 33% identity to a lytic transglycolase (MltA) from Escherichia coli and has been shown to be involved in the degradation of both insoluble murein sacculi and unsubstituted glycan strands. To study the function of the gene and its role in pathogenesis and virulence, a knockout mutant of a Neisseria **meningitidis** serogroup B strain was generated. The mutant exhibited retarded growth in vitro. Transmission electron microscopy revealed that the mutant grows in clusters which are connected by a continuous outer membrane, suggesting a failure in the separation of daughter cells. Moreover, **sodium dodecyl** sulfate-**polyacrylamide gel electrophoresis** analysis of culture supernatant revealed that the mutant releases several **proteins** in the medium. The five most abundant **proteins**, identified by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry analysis, belong to the outer membrane **protein** family. Finally, the mutant showed an attenuated phenotype, since it was not able to cause bacteremia in the infant rat model. We conclude that GNA33 is a

highly conserved lipoprotein which plays an important role in peptidoglycan metabolism, cell separation, membrane architecture, and virulence.

7/3,AB/4 (Item 4 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

12338630 References: 52
TITLE: Analysis of lipooligosaccharide biosynthesis in the Neisseriaceae
AUTHOR(S): Arking D; Tong YH; Stein DC (REPRINT)
AUTHOR(S) E-MAIL: DS64@UMAIL.UMD.EDU
CORPORATE SOURCE: Univ Maryland, Dept Cell Biol & Mol Genet, /College Pk//MD/20742 (REPRINT); Univ Maryland, Dept Cell Biol & Mol Genet, /College Pk//MD/20742
PUBLICATION TYPE: JOURNAL
PUBLICATION: JOURNAL OF BACTERIOLOGY, 2001, V183, N3 (FEB), P934-941
GENUINE ARTICLE#: 393FX
PUBLISHER: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
ISSN: 0021-9193
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: Neisserial lipooligosaccharide (LOS) contains three oligosaccharide chains, termed the alpha, beta, and gamma chains. We used Southern hybridization experiments on DNA **isolated** from various Neisseria spp. to determine if strains considered to be nonpathogenic possessed DNA sequences homologous with genes involved in the biosynthesis of these oligosaccharide chains. The presence or absence of specific genes was compared to the LOS profiles expressed by each strain, as characterized by their mobilities on **sodium dodecyl** sulfate-**polyacrylamide gel electrophoresis** gel and their reactivities with various LOS-specific monoclonal antibodies. A great deal of heterogeneity was seen with respect to the presence of genes encoding glycosylransferases in Neisseria. All pathogenic species were found to possess DNA sequences homologous with the Igt gene cluster, a group of genes needed for the synthesis of the a chain. Some of these genes were also found to be present in strains considered to be nonpathogenic, such as Neisseria lactamica, N. subflava, and N. sicca. Some nonpathogenic Neisseria spp. were able to express high-molecular-mass LOS structures, even though they lacked the DNA sequences homologous with rfaF, a gene whose product must act before gonococcal and **meningococcal** LOS can be elongated. Using a PCR amplification strategy, in combination with DNA sequencing, we demonstrated that N. subflava 44 possessed IgtA, IgtB, and lgtE genes. The predicted amino acid sequence encoded by each of these genes suggested that they encoded functional **proteins**; however, structural analysis of LOS **isolated** from this strain indicated that the bulk of its LOS was not modified by these gene products. This suggests the existence of an additional regulatory mechanism that is responsible for the limited expression of these genes in this strain.

7/3,AB/5 (Item 5 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

11602004 References: 37
TITLE: Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread
AUTHOR(S): Jelfs J; Munro R; Wedege E; Caugant DA (REPRINT)

AUTHOR(S) E-MAIL: dominique.caugant@folkehelsa.no
CORPORATE SOURCE: Natl Inst Publ Hlth, Dept Bacteriol, POB 4404 Torshov/N-0403 Oslo//Norway/ (REPRINT); Natl Inst Publ Hlth, Dept Bacteriol, /N-0403 Oslo//Norway/; Natl Inst Publ Hlth, Dept Vaccinol, /N-0403 Oslo//Norway/; S Western Area Pathol Serv, Dept Microbiol & Infect Dis, /Liverpool/NSW 2170/Australia/
PUBLICATION TYPE: JOURNAL
PUBLICATION: CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2000, V7, N3 (MAY), P390-395
GENUINE ARTICLE#: 311FB
PUBLISHER: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
ISSN: 1071-412X
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: The ET-15 clone,within the electrophoretic type (ET)-37 complex of Neisseria **meningitidis** was first detected in Canada in 1986 and has since been associated with outbreaks of **meningococcal** disease in many parts of the world. While the majority of the strains of the ET-37 complex are serosubtype P1,5,2, serosubtype determination of ET-15 strains may often be incomplete, with either only one or none of the two variable regions (VRs) of the serosubtype PorA outer membrane **protein** reacting with monoclonal antibodies. DNA sequence analysis of the porA gene from ET-15 strains with one or both unidentified serosubtype determinants was undertaken to identify the genetic basis of the lack of reaction with the monoclonal antibodies, Fourteen different porA alleles were identified among 38 ET-15 strains from various geographic origins, The sequences corresponding to subtypes P1,Sa,10d, P1,5,2, P1,5,10d, P1,5a,10k, and PI,Sa,10a were identified in 18, 11, 2, 2, and 1 **isolate**, respectively. Of the remaining four strains, which all were nonserosubtypeable, two had a stop codon within the VRI and the VR2, respectively, while in the other two the pol A gene was interrupted by the insertion element, IS1301, Of the strains with P1,5,2 sequence, one had a stop codon between the VR1 and VR2, one had a four-amino-acid deletion outside the VR2, and another showed no expression of PorA on **sodium dodecyl** sulfate-**polyacrylamide gel electrophoresis**,
Our results reveal that numerous genetic events have occurred in the porA gene of the ET-15 clone in the short time of its epidemic spread. The magnitude of microevolutionary mechanisms available in **meningococci** and the remarkable genetic flexibility of these bacteria need to be considered in relation to PorA vaccine development.

7/3,AB/6 (Item 6 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

10269989 References: 27
TITLE: Production, isolation and purification of bacteriocins expressed by two strains of Neisseria meningitidis
AUTHOR(S): Allunans J (REPRINT); Bjoras M; Seeberg E; Bovre K
CORPORATE SOURCE: Univ Oslo, Rikshosp, /Oslo//Norway/ (REPRINT); Univ Oslo, Rikshosp, /Oslo//Norway/
PUBLICATION TYPE: JOURNAL
PUBLICATION: APMIS, 1998, V106, N12 (DEC), P1181-1187
GENUINE ARTICLE#: 165VC
PUBLISHER: MUNKSGAARD INT PUBL LTD, 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
ISSN: 0903-4641
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: The systemic Neisseria **meningitidis** strain P241 and the healthy pharyngeal carrier strain BT878 produce bacteriocin-like substances during growth. A method has been devised for obtaining the active substances in solution. The activity was **recovered** by freeze-thaw extraction of dialyzed Todd-Hewitt agar medium into which the bacteriocins had diffused during growth of the producer strains. The bacteriocins were purified more than 50-fold by ammonium-sulphate precipitation and hydrophobic interaction chromatography. They are quite stable to heat and remain active 100% after 30 min at 100 degrees C. However, the **protein** nature of the bacteriocins has been confirmed by their sensitivity to alpha-chymotrypsin. Gel filtration indicated an M-r of 100-110 kDa, whereas **SDS-polyacrylamide gel electrophoresis** produced a common band by Coomassie staining corresponding to an M-r of 47-48 kDa, suggesting a dimer form of the active **protein** component.

7/3,AB/7 (Item 7 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

08104716 References: 43
TITLE: N-terminal amino acid sequences of the major outer membrane **proteins** from a Neisseria **meningitidis** group B strain **isolated** in Brazil
AUTHOR(S): DeSimone SG (REPRINT); Soares SAF; Souza ALA; Danelli MGM
CORPORATE SOURCE: INST OSWALDO CRUZ,DEPT BIOQUIM & BIOL MOL, LAB MICROSEQUENCIAMENTO PROT, AV BRASIL 4365/BR-21040900 RIO DE JANEIRO//BRAZIL/ (REPRINT); FIOCRUZ MS,INST TECNOL, DEPT DESENVOLVIMENTO TECNOL, LAB VACINAS BACTERIANAS/BR-21040900 RIO DE JANEIRO//BRAZIL/; INST BIOL,DEPT BIOL CELULAR & MOL/NITEROI/RJ/BRAZIL/
PUBLICATION TYPE: JOURNAL
PUBLICATION: MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1996, V91, N1 (JAN-FEB), P 111-116
GENUINE ARTICLE#: WC685
PUBLISHER: FUNDACO OSWALDO CRUZ, AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
ISSN: 0074-0276
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: The four dominant outer membrane **proteins** (46, 38, 33 and 28 kDa) were detected by **sodium dodecyl** sulfate-**polyacrylamide gel electrophoresis** (**SDS-PAGE**) in a semi-purified preparation of vesicle membranes of a Neisseria **meningitidis** (N44/89, B:4:P1.15:P5.5,7) strain **isolated** in Brazil. The N-terminal amino acid sequence for the 46 kDa and 28 kDa **proteins** matched that reported by others for class 1 and 5 **proteins** respectively, whereas the sequence (25 amino acids) for the 38 kDa (class 3) **protein** was similar to class I **meningococcal proteins**. The sequence for the 33 kDa (class 4) was unique and not homologous to any known **protein**.

7/3,AB/8 (Item 8 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

07731711 References: 32
TITLE: Human immune response to epitopes on the meningococcal outer

membrane class 5 protein following natural infection
AUTHOR(S): Danelli MGM (REPRINT) ; Alves CMA; Bastos RC; Batoreu NM; Barroso DE; Peralta JM; Frasch CE
CORPORATE SOURCE: UNIV FED RIO DE JANEIRO,INST MICROBIOL/BR-21941 RIO DE JANEIRO//BRAZIL/ (REPRINT); UNIV FED RIO DE JANEIRO,INST MICROBIOL/BR-21941 RIO DE JANEIRO//BRAZIL/; UNIV FED RIO DE JANEIRO,FDN OSWALDO CRUZ, INST TECNOL IMUNOBIOL BIOMANGUINHOS/RIO DE JANEIRO//BRAZIL/ ; UNIV FED RURAL RIO DE JANEIRO,INST VET, DEPT EPIDEMIOL & SAUDE PUBL/RIO DE JANEIRO//BRAZIL/; FDN OSWALDO CRUZ,INST OSWALDO CRUZ, DEPT TROP MED/RIO DE JANEIRO//BRAZIL/; US FDA,CTR BIOL EVALUAT & RES/BETHESDA//MD/
PUBLICATION TYPE: JOURNAL
PUBLICATION: FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1996, V15, N2-3 (SEP), P159-168
GENUINE ARTICLE#: VG614
PUBLISHER: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
ISSN: 0928-8244
LANGUAGE: English DOCUMENT TYPE: ARTICLE

ABSTRACT: Two monoclonal antibodies (mAbs) were produced against a serogroup B Neisseria **meningitidis** strain. These mAbs recognized two epitopes in the class 5outer membrane **proteins** (OMP), designated P5.7 and P5.Bm, and were able tokill the homologous strain through complement activation. Both epitopes were surface exposed and 68% of group B **meningococcal** clinical **isolates** had one or both epitopes present in their class 5 OMP. Antibodies to one or bothepitopes were demonstrated in 17 patients with **meningococcal** meningitis using an ELISA inhibition assay. Of the 17 paired sera, 41% and 29% of the acute-phase sera had antibodies to the P5.7 and P5.Bm epitopes, respectively.Immunoglobulin G to P5.Bm were found in all 17 convalescent-phase sera while specific antibodies against P5.7 were only found in 6 of these sera. These results demonstrate the potential importance of the P5.Bm and P5.7 epitopes on the class 5 OMP as candidates for vaccine composition.

7/3,AB/9 (Item 9 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

07178136 References: 22
TITLE: RIFAMPIN RESISTANCE IN NEISSERIA MENINGITIDIS DUE TO ALTERATIONS IN MEMBRANE PERMEABILITY
AUTHOR(S): ABADI FJR; CARTER PE (Reprint); CASH P; PENNINGTON TH
CORPORATE SOURCE: UNIV ABERDEEN,SCH MED,DEPT MED MICROBIOL,FORESTERHILL/ABERDEEN AB9 2ZD//SCOTLAND/ (Reprint); UNIV ABERDEEN,SCH MED,DEPT MED MICROBIOL/ABERDEEN AB9 2ZD//SCOTLAND/
PUBLICATION: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, V40, N3 (MAR), P 646-651
GENUINE ARTICLE#: TY366
ISSN: 0066-4804
LANGUAGE: ENGLISH DOCUMENT TYPE: ARTICLE

ABSTRACT: Rifampin-resistant (Rif(r)) Neisseria **meningitidis** strains are known to have single point mutations in the central conserved regions of the rpoB gene, We have demonstrated two distinct resistance phenotypes in strains with identical mutations in this region, an intermediate level of resistance in Rif(r) clinical **isolates** and a high level of resistance in mutants selected in vitro. The possible role of membrane permeability in the latter was investigated by measuring MICs in the presence of Tween 80; values for high-level-resistance mutants were reduced

to intermediate levels, whereas those for intermediate-level-resistance strains were unaffected. The highly resistant mutants were also found to have increased resistance to Triton X-100 and gentian violet. Sequencing of the **meningococcal** mtrR gene and its promoter region (which determine resistance to hydrophobic agents in Neisseria gonorrhoeae) from susceptible or intermediate strains and highly resistant mutants generated from them showed no mutation within this region, Two-dimensional **gel electrophoresis** of two parent and Rif mutant strains showed identical shifts in the pi of one **protein**, indicating that differences between the parent and the highly Rif(r) mutant are not confined to the rpoB gene, These results indicate that both permeability and rpoB mutations play a role in determining the resistance of N. **meningitidis** to rifampin.

7/3,AB/10 (Item 10 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

03739187 References: 37
TITLE: COMMON ANTIGENIC DOMAINS IN TRANSFERRIN-BINDING PROTEIN-2 OF NEISSERIA-MENINGITIDIS, NEISSERIA-GONORRHOEAE, AND HAEMOPHILUS-INFLUENZAE TYPE-B
AUTHOR(S): STEVENSON P; WILLIAMS P; GRIFFITHS E (Reprint)
CORPORATE SOURCE: NATL INST BIOL STAND & CONTROLS,BLANCHE LANE/POTTERS BAR EN6 3QG/HERTS/ENGLAND/ (Reprint); NATL INST BIOL STAND & CONTROLS,BLANCHE LANE/POTTERS BAR EN6 3QG/HERTS/ENGLAND/; UNIV NOTTINGHAM,DEPT PHARMACEUT SCI/NOTTINGHAM NG7 2RD//ENGLAND/
PUBLICATION: INFECTION AND IMMUNITY, 1992, V60, N6 (JUN), P2391-2396
GENUINE ARTICLE#: HX421
LANGUAGE: ENGLISH DOCUMENT TYPE: ARTICLE

ABSTRACT: There is now considerable evidence to show that in the Neisseria and Haemophilus species, membrane receptors specific for either transferrin or lactoferrin are involved in the acquisition of iron from these glycoproteins. In Neisseria **meningitidis**, the transferrin receptor appears to consist of two **proteins**, one of which (TBP 1) has an M(r) of 95,000 and the other of which (TBP 2) has an M(r) ranging from 68,000 to 85,000, depending on the strain; TBP 2 binds transferrin after **sodium dodecyl** sulfate-**polyacrylamide gel electrophoresis** and electroblotting, but TBP 1 does not do so. The relative contributions of these two **proteins** to the binding reaction observed with intact cells and to iron uptake are presently unknown. However, they are being considered as potential components of a group B **meningococcal** vaccine. Analogous higher- and lower-molecular-weight **proteins** associated with transferrin binding have been found in N. gonorrhoeae and Haemophilus influenzae. Previous work with polyclonal antibodies raised in mice with whole cells of iron-restricted N. **meningitidis** showed that the **meningococcal** TBP 2 exhibits considerable antigenic heterogeneity. Here, we report that antiserum against purified TBP 2 from one strain of N. **meningitidis** cross-reacts on immunoblotting with the TBP 2 of all **meningococcal isolates** examined, as well as with the TBP 2 of N. gonorrhoeae. This antiserum also cross-reacted with the TBP 2 of several strains of H. influenzae type b, thus showing the presence of common antigenic domains among these functionally equivalent **proteins** in different pathogens; no cross-reaction was detected with a purified sample of the human transferrin receptor.

7/3,AB/11 (Item 11 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

03474473 References: 33
TITLE: ROLE OF HORIZONTAL GENETIC EXCHANGE IN THE ANTIGENIC VARIATION OF THE CLASS-1 OUTER MEMBRANE PROTEIN OF NEISSERIA-MENINGITIDIS
AUTHOR(S): FEAVERS IM; HEATH AB; BYGRAVES JA; MAIDEN MCJ
CORPORATE SOURCE: NATL INST BIOL STAND & CONTROLS,DIV BACTERIOL,BLANCHE LANE/POTTERS BAR EN6 3QG/HERTS/ENGLAND/ (Reprint); NATL INST BIOL STAND & CONTROLS,DIV INFORMAT/POTTERS BAR EN6 3QG/HERTS/ENGLAND/
PUBLICATION: MOLECULAR MICROBIOLOGY, 1992, V6, N4 (FEB), P489-495
GENUINE ARTICLE#: HE853
LANGUAGE: ENGLISH DOCUMENT TYPE: ARTICLE

ABSTRACT: The nucleotide sequences of the genes encoding the class 1 outer membrane **protein** of Neisseria **meningitidis** (PorA) from 15 **meningococcal isolates** have been examined. These strains, **isolated** over a number of years, represented a variety of serological types, clonal groups, and geographical locations. Analysis of the aligned nucleotide sequences showed that the known serological relationships between these **proteins** were not necessarily reflected throughout the nucleotide sequences of their genes. The uneven distribution of base substitutions, revealed by a comparison of the informative bases, suggested that these genes possessed a mosaic structure. This structure probably resulted from the horizontal transfer of DNA between strains and would have contributed to both the generation and the spread of novel antigenic variants of the **protein**. In addition, the nucleotide differences between porA genes from different strains were not consistent with the nucleotide sequence divergence of the whole chromosome, as indicated by pulsed-field **gel electrophoresis** (PFGE) fingerprinting techniques: some strains with divergent PFGE fingerprints shared porA genes with extensive regions of nucleotide sequence identity and, conversely, some strains with similar chromosome structures possessed porA genes with different nucleotide sequences and serological properties. This suggested that entire genes had been exchanged between strains. Given that the **meningococcal** class 1 OMP is a major component in novel vaccines, some of which are currently undergoing field trials, the potential of horizontal genetic exchange to generate antigenic diversity has implications for the design of such vaccines.

7/3,AB/12 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

02050016
Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
Campylobacter Glycolsyltransferasen zur Verwendung bei der Biosynthese von Gangliosiden und ganglioside Imitatoren
Glycosyltransferases de campylobactre pour la biosynthese de gangliosides et de mimetiques de gangliosides
PATENT ASSIGNEE:
NATIONAL RESEARCH COUNCIL OF CANADA, (487628), Intellectual Property Services, EG-12, Bldg. M-58, Montreal Road, Ottawa, Ontario K1A 0R6, (CA), (Applicant designated States: all)
INVENTOR:
Gilbert, Michel, 116-101 Sacre-coeur, Hull,Quebec, J8X 1C7, (CA)
Wakarchuk, Warren W., 11-837 Eastvale Drive, Gloucester,Ontario, K1J 7T5, (CA)
LEGAL REPRESENTATIVE:

MacLean, Martin Robert et al (91311), Mathys & Squire 120 Holborn, London EC1N 2SQ, (GB)
PATENT (CC, No, Kind, Date): EP 1652927 A2 060503 (Basic)
EP 1652927 A3 060719
APPLICATION (CC, No, Date): EP 2005025316 000201;
PRIORITY (CC, No, Date): US 118213 P 990201; US 495406 000131
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
RELATED PARENT NUMBER(S) - PN (AN):
EP 1147200 (EP 2000901455)
INTERNATIONAL CLASSIFICATION (V8 + ATTRIBUTES):
IPC + Level Value Position Status Version Action Source Office:
C12N-0009/10 A I F B 20060101 20060615 H EP
C12N-0015/54 A I L B 20060101 20060615 H EP
C12N-0009/12 A I L B 20060101 20060615 H EP
C12Q-0001/68 A I L B 20060101 20060615 H EP

ABSTRACT EP 1652927 A2
This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an alpha2,3- and an alpha2,8-activity. A beta1,4-GalNAc transferase and a beta1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.
ABSTRACT WORD COUNT: 79
NOTE:
Figure number on first page: 2

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200618	1910
SPEC A	(English)	200618	22539
Total word count - document A			24458
Total word count - document B			0
Total word count - documents A + B			24458

7/3,AB/13 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

02041989
Neisseria antigens and compositions
Neisseria Meningitidis Antigene und Zusammenstellungen
Antigenes de Neisseria meningitidis et compositions
PATENT ASSIGNEE:
CHIRON CORPORATION, (572530), 4560 Horton Street, Emeryville, California 94608, (US), (Applicant designated States: all)
THE INSTITUTE FOR GENOMIC RESEARCH, (2152391), 9212 Medical Center Drive, Rockville,Maryland 20850, (US), (Applicant designated States: all)
INVENTOR:
Fraser, Claire, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Galeotti, Cesirea,Chiron SRL, Via Fiorentina, 1, 53100 Siena, (IT)
Grandi, GuidoChirron SRL, Via Fiorentina, 1, 53100 Siena, (IT)

Hickey, Erin, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Masignani, Vega,Chiron SRL, Via Fiorentina, 1, 53100 Siena, (IT)
Mora, Mariarosa,Chiron SRL, Via Fiorentina, 1, 53100 Siena, (IT)
Petersen, Jeremy, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Pizza, Mariagrazia,Chiron SRL, Via Fiorentina, 1, 53100 Siena, (IT)
Rappuoli, Rino,Chiron SRL, Via Fiorentina, 1, 53100 Siena, (IT)
Ratti, Giulio,Chiron SRL, Via Fiorentina, 1, 53100 Siena, (IT)
Scalato, Enzo,Chiron SRL, Via Fiorentina, 1, 53100 Siena, (IT)
Scarselli, Maria,Chiron SRL, Via Fiorentina, 1, 53100 Siena, (IT)
Tettelin, Herve, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Venter, J. Craig, 9712 Medical Center Drive, Rockville, MD 20850, (US)
LEGAL REPRESENTATIVE:
Marshall, Cameron John et al (92802), Carpmaels & Ransford 43-45 Bloomsbury Square, London WC1A 2RA, (GB)
PATENT (CC, No, Kind, Date): EP 1645631 A2 060412 (Basic)
EP 1645631 A3 060419
APPLICATION (CC, No, Date): EP 2005077865 990430;
PRIORITY (CC, No, Date): US 83758 P 980501; US 94869 P 980731; US 98994 P 980902; US 99062 P 980902; US 103749 P 981009; US 103794 P 981009; US 103796 P 981009; US 121528 P 990225
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 1093517 (EP 99922752)
INTERNATIONAL CLASSIFICATION (V8 + ATTRIBUTES):

IPC + Level Value	Position	Status	Version	Action	Source	Office:
C12N-0015/31	A	I	F	B	20060101	20060221 H EP
C07K-0014/22	A	I	L	B	20060101	20060221 H EP
C07K-0016/12	A	I	L	B	20060101	20060221 H EP
C12Q-0001/68	A	I	L	B	20060101	20060221 H EP
A61K-0039/095	A	I	L	B	20060101	20060221 H EP
G01N-0033/50	A	I	L	B	20060101	20060221 H EP

ABSTRACT EP 1645631 A3
The invention provides proteins from Neisseria gonorrhoeae and Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
ABSTRACT WORD COUNT: 33

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200615	842
SPEC A	(English)	200615	22082
Total word count - document A			22929
Total word count - document B			0
Total word count - documents A + B			22929

7/3,AB/14 (Item 3 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

02003094
Surface protein of Neisseria bacteria
Oberflachenprotein aus Neisserien
Proteine de surface du Neisseria
PATENT ASSIGNEE:
Center for Disease Control Department of Health Taiwan, (4915100), No. 6

Linshen S. Rd., Taipei, Taiwan 100 R.O.C., (TW), (Applicant designated States: all)
INVENTOR:
Yang, Chiou-Ying, No. 336, 5F., Ho Tso St., 402 Taichung, (TW)
LEGAL REPRESENTATIVE:
Beck, Michael Rudolf et al (88721), Beck & Rossig European Patent Attorneys Cuvilliesstrasse 14, 81679 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 1612218 A1 060104 (Basic)
APPLICATION (CC, No, Date): EP 2004015231 040629;
DESIGNATED STATES: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR
EXTENDED DESIGNATED STATES: AL; HR; LT; LV; MK
INTERNATIONAL CLASSIFICATION (V8 + ATTRIBUTES):
IPC + Level Value Position Status Version Action Source Office:
C07K-0014/22 A I F B 20060101 20050322 H EP
C12N-0015/31 A I L B 20060101 20050322 H EP

ABSTRACT EP 1612218 A1
The present invention provides a monoclonal antibody binding to Neisseria bacteria and its target antigen Ag473, which include the sequences of its polynucleotide and its amino acid, wherein the Neisseria bacteria can be Neisseria meningitidis or Neisseria gonorrhoeae; and wherein Ag473 can be made into a vaccine or a diagnostic or therapeutic reagent.
ABSTRACT WORD COUNT: 54
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200601	118
SPEC A	(English)	200601	2566
Total word count - document A			2684
Total word count - document B			0
Total word count - documents A + B			2684

7/3,AB/15 (Item 4 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01993144
Neisseria genomic sequences and methods of their use
Genomische Sequenzen von Neisseria und Verfahren zu ihrer Verwendung
Sequences genomiques de neisseria et methodes pour leur utilisation
PATENT ASSIGNEE:
CHIRON CORPORATION, (572530), 4560 Horton Street, Emeryville, California 94608, (US), (Applicant designated States: all)
THE INSTITUTE FOR GENOMIC RESEARCH, (2152390), 9712 Medical Center Drive, Rockville, Maryland 20850, (US), (Applicant designated States: all)
INVENTOR:
Pizza, Mariagrazia, Chiron Srl Via Fiorentina 1,, 53100 Siena, (IT)
Hickey, Erin, The institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Peterson, J., The institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Tettelin,Herve, The institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Masignani, Vega, Chiron Srl Via Fiorentina 1,, 53100 Siena, (IT)

Galeotti, Cesira, Chiron Srl Via Fiorentina 1,, 53100 Siena, (IT)
Mora, Marirosa, Chiron Srl Via Fiorentina 1,, 53100 Siena, (IT)
Ratti, Giulio, Chiron Srl Via Fiorentina 1,, 53100 Siena, (IT)
Scarselli, Maria, Chiron Srl Via Fiorentina 1,, 53100 Siena, (IT)
Scarlato, Vincenzo, Chiron Srl Via Fiorentina 1,, 53100 Siena, (IT)
Rappuoli, Rino, Chiron Srl Via Fiorentina 1,, 53100 Siena, (IT)
Fraser, Claire M., Chiron Corporation 4560 Horton Street, Emeryville, CA 94608, (US)
Grandi, Guido, Chiron Srl Via Fiorentina 1,, 53100 Siena, (IT)
Venter, Craig,J The institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, (US)
LEGAL REPRESENTATIVE:
Marshall, Cameron John et al (92802), Carpmaels & Ransford 43-45 Bloomsbury Square, London WC1A 2RA, (GB)
PATENT (CC, No, Kind, Date): EP 1605061 A1 051214 (Basic)
APPLICATION (CC, No, Date): EP 2005075284 000308;
PRIORITY (CC, No, Date): US 132068 P 990430; WO 99US23573 991008; GB 4695 000228
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 1185691 (EP 2000910392)
INTERNATIONAL PATENT CLASS (V7): C12Q-001/68; C12N-015/11; C07K-014/22

ABSTRACT EP 1605061 A1
The invention provides methods of obtaining immunogenic proteins from genomic sequences including Neisseria, including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of Neisseria meningitidis B. The proteins so obtained are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.
ABSTRACT WORD COUNT: 47
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200550	622
SPEC A	(English)	200550	27369
Total word count - document A			27991
Total word count - document B			0
Total word count - documents A + B			27991

7/3,AB/16 (Item 5 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01936485
Neisseria genomic sequences and methods of their use
Genomische Sequenzen von Neisseria und Verfahren zu ihrer Verwendung
Sequences genomiques de neisseria et methode pour leur utilisation
PATENT ASSIGNEE:
CHIRON CORPORATION, (572530), 4560 Horton Street, Emeryville, California 94608, (US), (Applicant designated States: all)
THE INSTITUTE FOR GENOMIC RESEARCH, (2152390), 9712 Medical Center Drive, Rockville, Maryland 20850, (US), (Applicant designated States: all)
INVENTOR:
Fraser, Claire M., Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, (US)

Hickey, Erin, Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Peterson, Jeremy, Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Tettelin, Herve, Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Venter, J. Craig, Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, (US)
Masignani, Vega, Chiron Srl, Via Fiorentina 1, 53100 Siena, (IT)
Galeotti, Cesira Chiron Srl, Via Fiorentina 1, 53100 Siena, (IT)
Mora, Marirosa Chiron Srl, Via Fiorentina 1, 53100 Siena, (IT)
Ratti, Giulio Chiron Srl, Via Fiorentina 1, 53100 Siena, (IT)
Scarselli, Maria, Chiron Srl, Via Fiorentina 1, 53100 Siena, (IT)
Scarlato, Vincenzo, Chiron Srl, Via Fiorentina 1, 53100 Siena, (IT)
Rappuoli, Rino, Chiron Srl, Via Fiorentina 1, 53100 Siena, (IT)
Pizza, Mariagratia, Chiron Srl, Via Fiorentina 1, 53100 Siena, (IT)
Grandi, Guido, Chiron Srl, Via Fiorentina 1, 53100 Siena, (IT)
LEGAL REPRESENTATIVE:
Marshall, Cameron John et al (92802), Carpmaels & Ransford 43-45 Bloomsbury Square, London WC1A 2RA, (GB)
PATENT (CC, No, Kind, Date): EP 1559795 A2 050803 (Basic)
EP 1559795 A3 051109
APPLICATION (CC, No, Date): EP 2005075407 991008;
PRIORITY (CC, No, Date): US 103794 P 981009; US 132068 P 990430
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 1144998 (EP 99970470)
INTERNATIONAL PATENT CLASS (V7): C12Q-001/68; C12N-015/11; C07K-014/22

ABSTRACT EP 1559795 A2
The invention provides methods of obtaining immunogenic proteins from genomic sequences including Neisseria, including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of Neisseria meningitidis B. The proteins so obtained are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.
ABSTRACT WORD COUNT: 47
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200531	709
SPEC A	(English)	200531	27248
Total word count - document A			27957
Total word count - document B			0
Total word count - documents A + B			27957

7/3,AB/17 (Item 6 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01907206
Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis, compositions containing same and methods of use thereof
OMP85 PROTEINE VON NEISSERIA GONORRHOEAE UAND NEISSERIA MENINGITIDIS, ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN UND VERFAHREN ZUR ANWENDUNG DAVON

PROTEINES OMP85 DE NEISSERIA GONORRHOEAE ET DE NEISSERIA MENINGITIDIS, COMPOSITIONS RENFERMANT LESDITES PROTEINES ET METHODES D'UTILISATION CORRESPONDANTES
PATENT ASSIGNEE:
The University of Montana, (1637192), University Hall 116, Missoula, MT 59812, (US), (Applicant designated States: all)
INVENTOR:
Judd, Ralph C., 316 Wickiup, Florence, Montana 59833, (US)
Manning, Scott D., 2205 Westfield, Missoula, Montana 59801, (US)
LEGAL REPRESENTATIVE:
Hale, Stephen Geoffrey et al (31411), Bromhead Johnson, Kingsbourne House, 229-231 High Holborn, London WC1V 7DP, (GB)
PATENT (CC, No, Kind, Date): EP 1535928 A2 050601 (Basic)
EP 1535928 A3 050817
APPLICATION (CC, No, Date): EP 2005003039 981022;
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
RELATED PARENT NUMBER(S) - PN (AN):
EP 1123403 (EP 98953873)
INTERNATIONAL PATENT CLASS (V7): C07K-014/22; C12N-015/31; A61K-039/095

ABSTRACT EP 1535928 A2
Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof, as well as homologs and fusion products thereof, are useful in vaccine compositions for use in the protection of subjects against Neisserial disease such as non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies developed to these proteins and peptides are also useful in the vaccine compositions.
ABSTRACT WORD COUNT: 72
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200522	437
SPEC A	(English)	200522	17113
Total word count - document A			17550
Total word count - document B			0
Total word count - documents A + B			17550

7/3,AB/18 (Item 7 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01795126
Use of HCG derived peptides in the treatment of iatrogenic diseases
Verwendung von HCG Peptidderivate zur Behandlung von iatrogene Krankheiten
Utilisation de peptides derives de HCG dans le traitement d'affections iatrogenes
PATENT ASSIGNEE:
Biotempt B.V., (4401960), Hoge Linthorst 1, 7958 NZ Koekange, (NL), (Applicant designated States: all)
INVENTOR:
The designation of the inventor has not yet been filed
PATENT (CC, No, Kind, Date): EP 1466611 A1 041013 (Basic)
APPLICATION (CC, No, Date): EP 2003076022 030408;

DESIGNATED STATES: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PT; RO; SE; SI; SK; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK
INTERNATIONAL PATENT CLASS (V7): A61K-038/06; A61K-038/07; A61K-038/24; A61P-031/00

ABSTRACT EP 1466611 A1
The invention relates to the field of (veterinary) medicine and to the treatment of subjects (be it man or animal) that suffer from iatrogenic disease, i.e. experience problems or complications resulting from a medical treatment. The invention provides a method for modulating an iatrogenic event in a subject comprising providing said subject with a gene-regulatory peptide or functional analogue thereof.

Furthermore, the invention provides use of an NF-kappaB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of an additional pro-inflammatory cytokine response occurring after an iatrogenic event in a subject.
ABSTRACT WORD COUNT: 100

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200442	281
SPEC A	(English)	200442	8139
Total word count - document A			8420
Total word count - document B			0
Total word count - documents A + B			8420

7/3,AB/19 (Item 8 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01673042
Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
Arzneimittel zur Behandlung von infektiosen Krankheiten infolge Neisseria Meningitidis
Medicament pour le traitement des maladies causees par une infection de neisseria meningitidis
PATENT ASSIGNEE:
Braun, Jan Matthias, Dr., (4145490), Scheidtweilerstrasse 89, 50933 Koln, (DE), (Applicant designated States: all)
INVENTOR:
The designation of the inventor has not yet been filed
LEGAL REPRESENTATIVE:
Meyers, Hans-Wilhelm, Dr.Dipl.-Chem. et al (72541), Patentanwalte von Kreisler-Selting-Werner Postfach 10 22 41, 50462 Koln, (DE)
PATENT (CC, No, Kind, Date): EP 1374892 A1 040102 (Basic)
APPLICATION (CC, No, Date): EP 2002014397 020628;
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS (V7): A61K-039/095; A61P-031/04

ABSTRACT EP 1374892 A1
The subject of the invention is a medicament for the treatment of diseases due to infection by Neisseria meningitidis, which comprises

glycoconjugates and/or lipooligosaccharides (LOS) from commensal bacteria with cross-reactive antigens to Neisseria meningitidis and/or antibodies against such glycoconjugates and/or lipooligosaccharides.
ABSTRACT WORD COUNT: 42
NOTE:
Figure number on first page: 1

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200401	390
SPEC A	(English)	200401	7642
Total word count - document A			8032
Total word count - document B			0
Total word count - documents A + B			8032

7/3,AB/20 (Item 9 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01324243
Bacterial RNaseP Proteins and their use in identifying antibacterial compounds
Bakterielle RNaseP Proteine und ihre Verwendung zum Identifizieren antibakterieller Verbindungen
Proteines de RNase P d'origine bacterienne et leur utilisation pour identifier des composes antibacteriens
PATENT ASSIGNEE:
Message Pharmaceuticals, Inc., (2941490), 30 Spring Mill Drive, Malvern, PA 19355, (US), (Applicant designated States: all)
THE OHIO STATE UNIVERSITY, (402131), 1960 Kenny Road, Columbus, OH 43210-1063, (US), (Applicant designated States: all)
INVENTOR:
Gopalan, Venkat, 5220 Brandy Oaks Lane, Columbus, Ohio 43210, (US)
Jovanovic, Milan, 6920 Sparrow Lane, Dublin, Ohio 43235, (US)
Eder, Paul S., 312 Wishman Avenue, Oreland, Pennsylvania 19075, (US)
Giordano, Tony, 38 North Spring Lane, Phoenixville, Pennsylvania 19460, (US)
Powers, Gordon D., 9 Lloyd Avenue, Malvern, Pennsylvania 19355, (US)
Xavier, K. Asish, 1155 Kingsway Road 4, West Chester, Pennsylvania 19382, (US)
LEGAL REPRESENTATIVE:
Grund, Martin, Dr. et al (90761), Dr. Volker Vossius, Patentanwaltskanzlei, Holbeinstrasse 5, 81679 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 1130091 A2 010905 (Basic)
EP 1130091 A3 011114
APPLICATION (CC, No, Date): EP 2001105007 010301;
PRIORITY (CC, No, Date): US 516061 000301
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS (V7): C12N-009/22; C12Q-001/18; C07K-016/12; C12N-015/63

ABSTRACT EP 1130091 A2
The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
ABSTRACT WORD COUNT: 23

NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200136	711
SPEC A	(English)	200136	8948
Total word count - document A			9659
Total word count - document B			0
Total word count - documents A + B			9659

7/3,AB/21 (Item 10 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01317505
METHOD AND COMPOSITION FOR TREATMENT AND/OR PREVENTION OF ANTIBIOTIC-RESISTANT MICROORGANISM INFECTIONS
METHODE UND ZUSAMMENSETZUNG ZUR BEHANDLUNG UND/ODER PROPHYLAXE VON ANTIBIOTIKUM-RESISTENTEN-MIKROORGANISMUS INFEKTIONEN
PROCEDE ET COMPOSITION POUR LE TRAITEMENT ET/OU LA PREVENTION D'INFECTIONS AUX MICRO-ORGANISMES RESISTANTS AUX ANTIBIOTIQUES
PATENT ASSIGNEE:
Sa Majeste la Reine du Chef du Canada Agriculture; et Agroalimentaire Canada, (3372910), Centre de Recherche et Developpement sur le bovin laitier et le Porc, Case Postale 90, 2000 Route 108 Est Lennoxville,Quebec J1M 1Z3, (CA), (Proprietor designated states: all)
INVENTOR:
DIARRA, Moussa, S., 1271, rue d'Orleans, Fleurimont, Quebec J1E 3P8, (CA)
LACASSE, Pierre, 4 Winder, Lennoxville, Quebec J1M 1L4, (CA)
PETITCLERC, Denis, 21 Boreigh, Lennoxville, Quebec J1M 2G4, (CA)
LEGAL REPRESENTATIVE:
Hinterberg, Katherine et al (98822), Cabinet Germain et Maureau, BP 6153, 69466 Lyon Cedex 06, (FR)
PATENT (CC, No, Kind, Date): EP 1246640 A2 021009 (Basic)
EP 1246640 B1 060419
WO 2001045732 010628
APPLICATION (CC, No, Date): EP 2000986923 001219; WO 2000CA1517 001219
PRIORITY (CC, No, Date): US 172577 P 991220
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS (V7): A61K-038/40; A61K-038/01; A61L-002/16; A01N-063/02; A61K-038/40; A61K-31:00; A61K-038/01; A61K-31:00; A61L-101/32; A61L-101:52
INTERNATIONAL CLASSIFICATION (V8 + ATTRIBUTES):

IPC + Level Value	Position	Status	Version	Action	Source	Office:
A61K-0038/40	A	I	F B 20060101	20051005	H	EP
A61K-0038/01	A	I	L B 20060101	20051005	H	EP
A61L-0002/16	A	I	L B 20060101	20051005	H	EP
A01N-0063/02	A	I	L B 20060101	20051005	H	EP
A61K-0045/00	A	I	L B 20060101	20051005	H	EP
A61P-0031/04	A	I	L B 20060101	20051005	H	EP

NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count

CLAIMS B	(English)	200616	530
CLAIMS B	(German)	200616	583
CLAIMS B	(French)	200616	709
SPEC B	(English)	200616	13953
Total word count - document A			0
Total word count - document B			15775
Total word count - documents A + B			15775

7/3,AB/22 (Item 11 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01209073
CLONING AND EXPRESSION OF HAEMOPHILUS SOMNUS TRANSFERRIN-BINDING PROTEINS
KLONIERUNG UND EXPRESSION VON HAEMOPHILUS SOMNUS TRANSFERRIN-BINDENDEN PROTEINEN
CLONAGE ET EXPRESSION DE PROTEINES SE LIANT A LA TRANSFERRINE DE HAEMOPHILUS SOMNUS
PATENT ASSIGNEE:
UNIVERSITY OF SASKATCHEWAN, (2506545), 120 Veterinary Road, Saskatoon, Saskatchewan S7N 5E3, (CA), (Proprietor designated states: all)
INVENTOR:
POTTER, Andrew, A., 521 Dalhousie Crescent, Saskatoon, Saskatchewan S7H 3S5, (CA)
RIOUX, Clement, 12 Croissant Barabe, Ile-Bizard, Quebec H9E 1J1, (CA)
SCHRYVERS, Anthony, B., 39 Edforth Road, NW, Calgary, Alberta T3A 3V8, (CA)
LEGAL REPRESENTATIVE:
Holliday, Louise Caroline (95451), D Young & Co 120 Holborn, London EC1N 2DY, (GB)
PATENT (CC, No, Kind, Date): EP 1159426 A1 011205 (Basic)
EP 1159426 B1 051221
WO 2000053765 000914
APPLICATION (CC, No, Date): EP 2000908866 000310; WO 2000CA244 000310
PRIORITY (CC, No, Date): US 267749 990310; US 405728 990924
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS (V7): C12N-015/31 ; C07K-014/285 ; A61K-039/102 ; G01N-033/68
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200551	761
CLAIMS B	(German)	200551	614
CLAIMS B	(French)	200551	875
SPEC B	(English)	200551	12905
Total word count - document A			0
Total word count - document B			15155
Total word count - documents A + B			15155

7/3,AB/23 (Item 12 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01196987

CAMPYLOBACTER GLYCOSYLTRANSFERASES FOR BIOSYNTHESIS OF GANGLIOSIDES AND GANGLIOSIDE MIMICS
CAMPYLOBACTER GLYCOLSYLTRANSFERASEN ZUR VERWENDUNG BEI DER BIOSYNTHESE VON GANGLIOSIDEN UND GANGLIOSIDE IMITATOREN
GLYCOSYLTRANSFERASES DE CAMPYLOBACTER POUR LA BIOSYNTHESE DE GANGLIOSIDES ET MIM TIQUES DE GANGLIOSIDES
PATENT ASSIGNEE:
NATIONAL RESEARCH COUNCIL OF CANADA, (487628), Intellectual Property Services, EG-12, Bldg. M-58, Montreal Road, Ottawa, Ontario K1A 0R6, (CA), (Proprietor designated states: all)
INVENTOR:
GILBERT, Michel, 116 - 101 Sacre-coeur, Hull, Quebec J8X 1C7, (CA)
WAKARCHUK, Warren, W., 11 - 837 Eastvale Drive, Gloucester, Ontario K1J 7T5, (CA)
LEGAL REPRESENTATIVE:
MacLean, Martin Robert et al (91311), Mathys & Squire 120 Holborn, London EC1N 2SQ, (GB)
PATENT (CC, No, Kind, Date): EP 1147200 A1 011024 (Basic)
EP 1147200 B1 060607
WO 2000046379 000810
APPLICATION (CC, No, Date): EP 2000901455 000201; WO 2000CA86 000201
PRIORITY (CC, No, Date): US 118213 P 990201; US 495406 000131
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO
RELATED DIVISIONAL NUMBER(S) - PN (AN):
EP 1652927 (EP 2005025316)
INTERNATIONAL PATENT CLASS (V7): C12N-015/54; C12N-009/10; C12N-009/12; C12Q-001/68
INTERNATIONAL CLASSIFICATION (V8 + ATTRIBUTES):
IPC + Level Value Position Status Version Action Source Office:
C12N-0015/54 A I F B 20060101 20000814 H EP
C12N-0009/10 A I L B 20060101 20000814 H EP
C12N-0009/12 A I L B 20060101 20000814 H EP
C12Q-0001/68 A I L B 20060101 20000814 H EP
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200623	2824
CLAIMS B	(German)	200623	2426
CLAIMS B	(French)	200623	3024
SPEC B	(English)	200623	22789
Total word count - document A			0
Total word count - document B			31063
Total word count - documents A + B			31063

7/3,AB/24 (Item 13 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01149650
MORAXELLA CATARRHALIS BASB034 POLYPEPTIDES AND USES THEREOF
MORAXELLA CATARRHALIS BASB034 POLYPEPTIDE UND VERWENDUNGEN DAVON
POLYPEPTIDES BASB034 DE MORAXELLA CATARRHALIS ET LEURS UTILISATIONS
PATENT ASSIGNEE:
Glaxosmithkline Biologicals S.A., (3870780), Rue de l'Institut 89, 1330 Rixensart, (BE), (Proprietor designated states: all)

INVENTOR:
RUELLE, Jean-Louis, SmithKline Beecham Biol. S.A., Rue de l'Institut 89, B-1330 Rixensart, (BE)
LEGAL REPRESENTATIVE:
Lubienski, Michael John (94434), GlaxoSmithKline Corporate Intellectual Property 980 Great West Road, Brentford, Middlesex TW8 9GS, (GB)
PATENT (CC, No, Kind, Date): EP 1114160 A1 010711 (Basic)
EP 1114160 B1 051214
WO 2000015802 000323
APPLICATION (CC, No, Date): EP 99946171 990914; WO 99EP6781 990914
PRIORITY (CC, No, Date): GB 9820002 980914
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: SI
INTERNATIONAL PATENT CLASS (V7): C12N-015/31; C07K-014/21; C12N-015/70; C12N-001/21; A61K-039/02; A61K-048/00; C07K-016/12; A61K-039/395
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200550	1049
CLAIMS B	(German)	200550	1002
CLAIMS B	(French)	200550	1101
SPEC B	(English)	200550	16782
Total word count - document A			0
Total word count - document B			19934
Total word count - documents A + B			19934

7/3,AB/25 (Item 14 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00913415
RECOMBINANT ALPHA-2,3-SIALYLTRANSFERASES AND THEIR USES
REKOMBINANTE ALPHA-2,3-SIALYLTRANSFERASEN UND DEREN VERWENDUNG
ALPHA-2,3-SIALYLTRANSFERASES RECOMBINANTES ET LEURS UTILISATIONS
PATENT ASSIGNEE:
National Research Council of Canada, (3297442), Intellectual Property Services Office, EG-10 Building M 58, Montreal Road, Ottawa, Ontario K1A 0R6, (CA), (Proprietor designated states: all)
INVENTOR:
GILBERT, Michel, 116-101 Sacre-Coeur, Hull, Quebec J8X 1C7, (CA)
WAKARCHUK, Warren, W., 11-837 Eastvale Drive, Gloucester, Ontario K1J 7T5, (CA)
YOUNG, N., Martin, 51 Eastpark Drive, Gloucester, Ontario K1B 3Z6, (CA)
JENNINGS, Michael, P., 20 Picasso Street, Carina, Brisbane, QLD 4152, (AU)
MOXON, Edward, Richard, 17 Moreton Road, Oxford OX2 7AX, (GB)
LEGAL REPRESENTATIVE:
Harding, Charles Thomas (70742), D. Young & Co. 21 New Fetter Lane, London EC4A 1DA, (GB)
PATENT (CC, No, Kind, Date): EP 906432 A1 990407 (Basic)
EP 906432 B1 040609
WO 1997047749 971218
APPLICATION (CC, No, Date): EP 97923695 970610; WO 97CA390 970610
PRIORITY (CC, No, Date): US 19520 P 960610; US 872485 970607
DESIGNATED STATES: CH; DE; DK; ES; FI; FR; GB; IE; IT; LI; SE
INTERNATIONAL PATENT CLASS (V7): C12N-015/54; C12N-015/70; C12N-015/79;

C12N-009/10; C12N-005/10; C12N-001/21; C12P-019/26
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200424	786
CLAIMS B	(German)	200424	736
CLAIMS B	(French)	200424	875
SPEC B	(English)	200424	11842
Total word count - document A			0
Total word count - document B			14239
Total word count - documents A + B			14239

7/3,AB/26 (Item 15 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00905071
MORAXELLA CATARRHALIS OUTER MEMBRANE PROTEIN OMP106, GENE SEQUENCE AND USES THEREOF
PROTEIN DER AUSSEREN MEMBRAN VON MORAXELLA CATARRHALIS OMP-106, DESSEN GENSEQUENZ UND DESSEN VERWENDUNG
PROTEINE DE LA MEMBRANE EXTERIEURE OMP106 DE MORAXELLA CATARRHALIS, SA SEQUENCE NUCLEOTIDIQUE ET SON UTILISATION
PATENT ASSIGNEE:
Antex Biologics, Inc., (1525991), 300 Professional Drive, Gaithersburg, MD 20879, (US), (Proprietor designated states: all)
INVENTOR:
TUCKER, Kenneth, 9014 Allington Manor Circle West, Frederick, Maryland 21703, (US)
PLOSILA, Laura, 110 Annandale Drive, Cary, NC 27511, (US)
LEGAL REPRESENTATIVE:
Horner, Martin Grenville et al (45941), Cruikshank & Fairweather 19 Royal Exchange Square, Glasgow G1 3AE Scotland, (GB)
PATENT (CC, No, Kind, Date): EP 900025 A1 990310 (Basic)
EP 900025 B1 030702
WO 97041731 971113
APPLICATION (CC, No, Date): EP 97926409 970428; WO 97US7679 970428
PRIORITY (CC, No, Date): US 642712 960503
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: LT; LV; RO
INTERNATIONAL PATENT CLASS (V7): A61K-039/095; A61K-039/40; C07K-014/22; C07K-016/12; C12N-015/31; C12Q-001/68; G01N-033/53
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200327	516
CLAIMS B	(German)	200327	463
CLAIMS B	(French)	200327	549
SPEC B	(English)	200327	14938
Total word count - document A			0
Total word count - document B			16466
Total word count - documents A + B			16466

7/3,AB/27 (Item 16 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00810621
ISOLATED FrpB NUCLEIC ACID MOLECULE AND VACCINE
ISOLIERTES FrpB NUKLEINSAUREMOLEKUL UND ENTSPRECHENDE IMPFSTOFF
MOLECULE ISOLEE D'ACIDE NUCLEIQUE DE PROTEINE B REGULEE PAR Fe (FrpB) ET VACCIN UTILISANT CETTE MOLECULE
PATENT ASSIGNEE:
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ; Office of Research Services , (751089), Campus Box No. 4100, 300 Bynum Hall, Chapel Hill, NC 27599-4100, (US), (Proprietor designated states: all)
INVENTOR:
SPARLING, P., Fredrick, Route 1, Box 980, Moncure, NC 27559, (US)
BEUCHER, Margaret, Apt. 5C, Greenwood Heights, Connellsville, PA 15425, (US)
LEGAL REPRESENTATIVE:
Grunecker, Kinkeldey, Stockmair & Schwanhausser Anwaltssozietat (100721), Maximilianstrasse 58, 80538 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 830456 A1 980325 (Basic)
EP 830456 B1 060621
WO 1996031618 961010
APPLICATION (CC, No, Date): EP 96912605 960408; WO 96US4774 960408
PRIORITY (CC, No, Date): US 418964 950407
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; IE; IT; LI; NL
INTERNATIONAL PATENT CLASS (V7): C12P-021/04; C12P-021/08; A61K-035/18; A61K-038/00; C07K-001/00; C07K-014/195; C07K-016/12; C07H-021/04; A61K-039/095;
INTERNATIONAL CLASSIFICATION (V8 + ATTRIBUTES):

IPC + Level	Value	Position	Status	Version	Action	Source	Office:
C12P-0021/04		A	I	F	B	20060101	19961121 H EP
C12P-0021/08		A	I	L	B	20060101	20010109 H EP
A61K-0035/18		A	I	L	B	20060101	20010109 H EP
A61K-0038/00		A	I	L	B	20060101	20010109 H EP
C07K-0001/00		A	I	L	B	20060101	20010109 H EP
C07K-0014/195		A	I	L	B	20060101	20010109 H EP
C07K-0016/12		A	I	L	B	20060101	20010109 H EP
C07H-0021/04		A	I	L	B	20060101	20010109 H EP
A61K-0039/095		A	I	L	B	20060101	20010109 H EP
C07K-0014/22		A	I	L	B	20060101	20010109 H EP

NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200625	174
CLAIMS B	(German)	200625	143
CLAIMS B	(French)	200625	191
SPEC B	(English)	200625	9242
Total word count - document A			0
Total word count - document B			9750
Total word count - documents A + B			9750

7/3,AB/28 (Item 17 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00787514

Transferrin-binding protein 1 (Tbp1) gene of Actinobacillus pleuropneumoniae, its use in vaccines for pleuropneumonia and as diagnostic reagents
Gen fur dem Tranferrin bindende Protein (Tbp1) aus Actinobacillus pleuropneumoniae, dessen Verwendung in Impfstoffen und als diagnostische Reagenz
Gene de la proteine de liaison de transferrine (Tbp1) d'Actinobacillus pleuropneumoniae, son utilisation dans des vaccins et comme agent diagnostique
PATENT ASSIGNEE:
LABORATORIOS HIPRA, S.A., (1902850), Avenida La Selva s/n, E-17170 Amer (Girona), (ES), (applicant designated states: AT;BE;DE;DK;FR;GB;GR;IE;IT;NL;PT;SE)
INVENTOR:
Daban, Montserrat, Mare de Deu de Montserrat Street No. 263, 08041 Barcelona, (ES)
Espuna, Enric, Av. Paraguay No. 9, 17800 Olot (Girona), (ES)
Medrano, Andres, Av. Can Serra No. X-51, 08906 Hospitalet de Llobregat(Barcelona), (ES)
Querol, Enrique, Vallmajor Street No. 35, 08021 Barcelona, (ES)
LEGAL REPRESENTATIVE:
Claeys, Pierre et al (171), GEVERS Patents, Brussels Airport Business Park, Holidaystraat 5, 1831 Diegem, (BE)
PATENT (CC, No, Kind, Date): EP 733708 A2 960925 (Basic)
EP 733708 A3 970115
APPLICATION (CC, No, Date): EP 96870033 960321;
PRIORITY (CC, No, Date): ES 95592 950324
DESIGNATED STATES: AT; BE; DE; DK; FR; GB; GR; IE; IT; NL; PT; SE
INTERNATIONAL PATENT CLASS (V7): C12N-015/31; C07K-014/285; A61K-039/102; C07K-016/12; G01N-033/569;

ABSTRACT EP 733708 A2
The present invention relates to the gene of transferrin-binding protein 1 (Tbp1) of Actinobacillus pleuropneumoniae, its use to prepare products for vaccination against porcine pleuropneumonia or as diagnostic reagents. The invention also relates to the use of Tbp1 or fragments thereof to produce monoclonal or polyclonal antibodies to be used as diagnostic reagents. The invention also relates to the use of Tbp1 or fragments thereof, alone or combined to other virulence factors of the pathogen, as vaccination products against porcine pleuropneumonia.
ABSTRACT WORD COUNT: 94

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPAB96	619
SPEC A	(English)	EPAB96	5159
Total word count - document A			5778
Total word count - document B			0
Total word count - documents A + B			5778

7/3,AB/29 (Item 18 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00646348
Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci

Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
Preparation et utilisations de proteines de membranes externes depouvues de LOS a partir de coques gram-negatifs
PATENT ASSIGNEE:
AMERICAN CYANAMID COMPANY, (212592), One Cyanamid Plaza, Wayne New Jersey 07470, (US), (Proprietor designated states: all)
INVENTOR:
Zlotnick, Gary W., 21 Woodlyn Way, Penfield, New York 14526, (US)
LEGAL REPRESENTATIVE:
Wachtershauser, Gunter, Prof. Dr. (12711), Patentanwalt, Tal 29, 80331 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 624376 A1 941117 (Basic)
EP 624376 B1 000315
APPLICATION (CC, No, Date): EP 94106827 940502;
PRIORITY (CC, No, Date): US 61581 930513
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
EXTENDED DESIGNATED STATES: SI
INTERNATIONAL PATENT CLASS (V7): A61K-039/095; A61K-039/40

ABSTRACT EP 624376 A1
Described herein is a method for removing toxic lipooligosaccharide (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis. LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.
ABSTRACT WORD COUNT: 56
NOTE:
Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200011	865
CLAIMS B	(German)	200011	798
CLAIMS B	(French)	200011	1006
SPEC B	(English)	200011	5445
Total word count - document A			0
Total word count - document B			8114
Total word count - documents A + B			8114

7/3,AB/30 (Item 19 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00536407
Pneumococcal polysaccharide conjugate vaccine
Imfpstoff, enthaltend ein Pneumokokkenpolysaccharid-Konjugat
Vaccin a base de conjugue de polysaccharide de pneumocoque
PATENT ASSIGNEE:
Merck & Co., Inc., (200479), 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;PT;SE)
INVENTOR:
Kniskern, Peter J., 841 Patterson Drive, Lansdale, PA 19446, (US)
Ip, Charlotte C., 1665 Chadwyck Place, Blue Bell, PA 19422, (US)
Hagopian, Arpi, 771 Hartley Drive, Lansdale, PA 19446, (US)

Hennessey Jr., John P., 114 Fox Hollow Road, Dublin, PA 18917, (US)
Miller, William J., 232 Old Church Road, North Wales, PA 19454, (US)
Kubek, Dennis J., 76 Carolina Avenue, Salem, West Virginia 26426, (US)
Burke, Pamela D., 862 Yorktown Street, Landsdale, PA 19446, (US)
Marburg, Stephen, 50 Concord Avenue, Metuchen, NJ 08840, (US)
Tolman, Richard L., 29 Upper Warren Way, Warren, NJ 07059, (US)
LEGAL REPRESENTATIVE:
Horgan, James Michael Frederic et al (86873), Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road, Harlow, Essex CM20 2QR, (GB)
PATENT (CC, No, Kind, Date): EP 497525 A2 920805 (Basic)
EP 497525 A3 930310
EP 497525 B1 980819
APPLICATION (CC, No, Date): EP 92300655 920127;
PRIORITY (CC, No, Date): US 646570 910128; US 807942 911219
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS (V7): A61K-039/385; A61K-039/09; A61K-039/095; A61K-039/295; A61K-039/02; A61K-047/48;

ABSTRACT EP 497525 A2
A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process. The conjugate is useful in the prevention of pneumococcal infections. Vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein (Pn-Ps-PRO) conjugates induce broadly protective recipient immune responses against the cognate pathogens from which the polysaccharide components are derived. Young children and infants younger than 2 years old, normally unable to mount a protective immune response to the Pn-Ps alone, exhibit protective immune responses upon vaccination with these Pn-Ps-PRO conjugates.
ABSTRACT WORD COUNT: 105

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9834	1182
CLAIMS B	(German)	9834	1225
CLAIMS B	(French)	9834	1373
SPEC B	(English)	9834	25880
Total word count - document A			0
Total word count - document B			29660
Total word count - documents A + B			29660

7/3,AB/31 (Item 20 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00536406
Polysaccharide antigens from streptococcus pneumoniae
Polysaccharidantigene aus Streptococcus pneumoniae
Antigenes polysaccharadiques a partir de Streptococcus pneumoniae
PATENT ASSIGNEE:
Merck & Co., Inc., (200479), 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, (US), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;GR;IT;LI;LU;NL;PT;SE)
INVENTOR:

Kniskern, Peter J., 841 Patterson Drive, Lansdale, PA 19446, (US)
Ip, Charlotte C., 1665 Chadwyck Place, Blue Bell, PA 19422, (US)
Hagopian, Arpi, 771 Hartley Drive, Lansdale, PA 19446, (US)
Hennessey Jr. John P., 114 Fox Hollow Road, Dublin, PA 18917, (US)
Miller, William J., 232 Old Church Road, North Wales, PA 19454, (US)
Kubek, Dennis J., 76 Carolina Avenue, Salem, West Virginia 26426, (US)
Burke, Pamela D., 862 Yorktown Street, Lansdale, PA 19446, (US)
LEGAL REPRESENTATIVE:
Horgan, James Michael Frederic et al (86873), Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road, Harlow, Essex CM20 2QR, (GB)
PATENT (CC, No, Kind, Date): EP 497524 A2 920805 (Basic)
EP 497524 A3 930310
EP 497524 B1 980715
APPLICATION (CC, No, Date): EP 92300654 920127;
PRIORITY (CC, No, Date): US 646573 910128; US 807941 911219
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; PT; SE
INTERNATIONAL PATENT CLASS (V7): A61K-039/09; C12P-019/04; C08B-037/00;

ABSTRACT EP 497524 A2

Type-specific capsular polysaccharide preparations from Streptococcus pneumoniae, having on average less than about 1000 oligosaccharide repeat units per molecule, polydispersities between 1.0 and 1.4, intrinsic viscosities between 0.6 and 3.0 dL/g, and less than 3% contamination of type-specific polysaccharide by group-specific C-polysaccharide, are produced by a novel process. The novel type specific polysaccharide products are useful in the preparation of vaccines, especially covalent conjugates comprising the novel polysaccharide linked to a T-cell stimulatory carrier protein. Vaccines comprising the novel polysaccharides are useful in the prevention of infection and of diseases associated with infection by Streptococcus pneumoniae.

ABSTRACT WORD COUNT: 98
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9829	831
CLAIMS B	(German)	9829	845
CLAIMS B	(French)	9829	963
SPEC B	(English)	9829	22499
Total word count - document A			0
Total word count - document B			25138
Total word count - documents A + B			25138

7/3,AB/32 (Item 21 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00533711
Conjugates of the class II protein of the outer membrane of neisseria meningitidis and of HIV-1 related peptides.
Konjugate des Klasse-II-Proteins der ausseren Membran von Neisseria Meningitidis mit HIV-1-verwandten Peptiden.
Conjugues de la proteine classe II de la membrane exterieure de neisseria meningitidis et de peptides associes a HIV-1.
PATENT ASSIGNEE:
MERCK & CO. INC., (200479), 126, East Lincoln Avenue P.O. Box 2000, Rahway New Jersey 07065-0900, (US), (applicant designated states: CH;DE;FR;GB;IT;LI;NL)

INVENTOR:
Emini, A., 6 Faggs Manor Lane, Paoli, PA 19301, (US)
Liu, Margaret A., 4 Cushman Road, Rosemont, PA 19190, (US)
Marburg, Stephen, 50 Concord Avenue, Metuchen, NJ 08840, (US)
Tolman, Richard L., 29 Upper Warren Way, Warren, NJ 07059, (US)
LEGAL REPRESENTATIVE:
Thompson, John Dr. et al (62771), Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road, Harlow, Essex CM20 2QR, (GB)
PATENT (CC, No, Kind, Date): EP 519554 A1 921223 (Basic)
APPLICATION (CC, No, Date): EP 92201693 920611;
PRIORITY (CC, No, Date): US 715273 910619
DESIGNATED STATES: CH; DE; FR; GB; IT; LI; NL
INTERNATIONAL PATENT CLASS (V7): C07K-017/06; C07K-003/28; A61K-039/385; A61K-039/21;

ABSTRACT EP 519554 A1
The Class II major immuno-enhancing protein (MIEP) of Neisseria meningitidis, purified directly from the outer membrane of Neisseria meningitidis, or obtained through recombinant cloning and expression of DNA encoding the MIEP of Neisseria meningitidis, has immunologic carrier as well as immunologic enhancement and mitogenic properties. Conjugates of this protein and HIV-1 related peptides are useful for the induction of mammalian immune responses directed against the peptides, against HIV-1 strains, and for the neutralization of HIV-1 and prevention of HIV-I related diseases.
ABSTRACT WORD COUNT: 83

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	1279
SPEC A	(English)	EPABF1	17403
Total word count - document A			18682
Total word count - document B			0
Total word count - documents A + B			18682

7/3,AB/33 (Item 22 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00515555
Monoclonal antibodies binding determinants of gram negative bacteria.
Monoklonale Antikorper, die Determinanten von Gram-negativen Bakterien binden.
Anticorps monoclonaux, determinants de bacteries gram-negatives qui lient.
PATENT ASSIGNEE:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, (221076), 2199 Addison Street, Berkeley, California 94720, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
Young, Lowell S., 2025 Hackson Street, San Francisco, California 94109, (US)
LEGAL REPRESENTATIVE:
Armitage, Ian Michael et al (27762), MEWBURN ELLIS 2 Cursitor Street, London EC4A 1BQ, (GB)
PATENT (CC, No, Kind, Date): EP 494085 A1 920708 (Basic)
APPLICATION (CC, No, Date): EP 92104180 860819;
PRIORITY (CC, No, Date): US 781242 850927
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

RELATED PARENT NUMBER(S) - PN (AN):
EP 217527
INTERNATIONAL PATENT CLASS (V7): C12P-021/08;

ABSTRACT EP 494085 A1
The present invention provides novel hybridoma cell lines which produce monoclonal antibodies (MoAbs) that bind epitopes found on lipopolysaccharide most commonly associated with the endotoxin core of gram negative bacteria and exhibit broad cross-reactivity with gram negative bacteria of different genera and effectively neutralize endotoxin. At least one of the MoAbs disclosed (XMMEN-J5D) binds an epitope also found on gram positive bacteria. The hybridomas are produced by fusing an immortal cell, a cell having the ability to replicate indefinitely in myeloma cell culture, and an effector immune cell following immunization of the immune cell host with a preparation of a gram negative bacteria. While several individual hybridoma cell lines producing monoclonal antibodies to lipopolysaccharide are described, the present invention adds to the state of the art an entire family of hybridomas producing monoclonal antibodies to lipopolysaccharide-associated epitopes.
The monoclonal antibodies produced by the hybridoma cell lines of the present invention are useful in the detection of bacterial infections, therapy and prophylaxis of bacterial endotoxemia and infection caused by gram negative bacteria.
ABSTRACT WORD COUNT: 173

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	422
SPEC A	(English)	EPABF1	14041
Total word count - document A			14463
Total word count - document B			0
Total word count - documents A + B			14463

7/3,AB/34 (Item 23 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00446976
A METHOD FOR ISOLATING AND PURIFYING TRANSFERRIN AND LACTOFERRIN RECEPTOR PROTEINS FROM BACTERIA AND THE PREPARATION OF VACCINES CONTAINING THE SAME
VERFAHREN ZUR ISOLIERUNG UND REINIGUNG VON REZEPTOREN FUR TRANSFERRIN UND LACTOFERRIN VON BAKTERIEN UND HERSTELLUNG VON IMPFSTOFFEN, DIE SIE ENTHALTEN
PROCEDE PERMETTANT D'ISOLER ET DE PURIFIER DES PROTEINES RECEPTRICES DE TRANSFERRINE ET DE LACTOFERRINE A PARTIR DE BACTERIES ET PREPARATION DE VACCINS CONTENAN
PATENT ASSIGNEE:
UNIVERSITY TECHNOLOGIES INTERNATIONAL INC., (1298540), ES620, 2500 University Drive, N.W., Galgary, Alberta T2N 1N4, (CA), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)
SCHRYVERS, Anthony Bernard, (1438060), 39 Edforth Road, N.W., Calgary, Alberta T3A 3A3, (CA), (applicant designated states: AT;BE;CH;DE;DK;ES;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
SCHRYVERS, Anthony, Bernard, 39 Edforth Road, N.W., Calgary, Alberta T3A 3A3, (CA)

LEGAL REPRESENTATIVE:
Bernasconi, Jean et al (13921), c/o Cabinet Lavoix, 2, Place d'Estienne d'Orves, 75441 Paris Cedex, (FR)
PATENT (CC, No, Kind, Date): EP 528787 A1 930303 (Basic)
EP 528787 B1 981202
WO 9012591 901101
APPLICATION (CC, No, Date): EP 90906093 900426; WO 90CA131 900426
PRIORITY (CC, No, Date): US 344356 890427; US 507481 900411
DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS (V7): A61K-039/095; A61K-039/102; A61K-039/02;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	9849	871
CLAIMS B	(German)	9849	845
CLAIMS B	(French)	9849	998
SPEC B	(English)	9849	6500
Total word count - document A			0
Total word count - document B			9214
Total word count - documents A + B			9214

7/3,AB/35 (Item 24 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00443912
MENINGOCOCCAL CLASS 1 OUTER-MEMBRANE PROTEIN VACCINE
MENINGOCOCCALES KLASSE I-AÜSSENMEMBRANPROTEIN-VAKZIN
VACCIN MENINGOCOQUE DE LA PROTEINE DE LA MEMBRANE EXTERNE DE LA CLASSE 1
PATENT ASSIGNEE:
AMERICAN CYANAMID COMPANY, (212595), One Portland Square, Portland, Maine 04101, (US), (Proprietor designated states: all)
De Staat der Nederlanden, represented by the Deputy Director-General of the RIVM of Bilthoven, (935230), Antonie van Leeuwenhoeklaan 9, NL-3720 BA Bilthoven, (NL), (Proprietor designated states: all)
INVENTOR:
SEID, Robert, C., Jr., 590 25th Avenue, San Francisco, CA 94121, (US)
PARADISO, Peter, R., 6 Guilford Way, Pittsford, NY 14534, (US)
POOLMAN, Jan, T., Leeteinde 8, NL-1151 AK Broek in Waterland, (NL)
HOOGERHOUT, Peter, Idenburgstraat 13, NL-2805 SZ Gouda, (NL)
WIERTZ, Emmanuel, J., H., J., Mauritsstraat 106, NL-3583 HW Utrecht, (NL)
VAN DER LEY, Peter, Adriaan van Ostadelaan 124, NL-3583 AM Utrecht, (NL)
HECKELS, John, Edward 6 Arun Way West Wellow, Romsey, Hampshire SO51 6GT, (GB)
CLARKE, Ian, Nicholas 15 Fernyhurst Avenue, Rownhams Southampton, Hampshire SO1 8DR, (GB)
LEGAL REPRESENTATIVE:
Roques, Sarah Elizabeth et al (79543), J.A. Kemp & Co. 14 South Square Gray's Inn, London WC1R 5JJ, (GB)
PATENT (CC, No, Kind, Date): EP 449958 A1 911009 (Basic)
EP 449958 B1 950322
EP 449958 B2 021113
EP 449958 B9 030528
WO 90006696 900628
APPLICATION (CC, No, Date): EP 90901397 891219; WO 89US5678 891219
PRIORITY (CC, No, Date): NL 883111 881219; NL 8936 890106; NL 891612 890626
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS (V7): A61K-039/095; C07K-014/22; C07K-007/04; A61K-039/39; A61K-039/385; C12N-015/31; C12N-015/62; C12N-15:31; C12R-1:36
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200322	2220
CLAIMS B	(German)	200322	2206
CLAIMS B	(French)	200322	2873
SPEC B	(English)	200322	14678
Total word count - document A			0
Total word count - document B			21977
Total word count - documents A + B			21977

7/3,AB/36 (Item 25 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00345951
Neisserial vaccines.
Neisseria-Vakzine.
Vaccins contre Neisseria.
PATENT ASSIGNEE:
THE ROCKEFELLER UNIVERSITY, (315600), 1230 York Avenue, New York, NY 10021, (US), (applicant designated states: BE;CH;DE;FR;GB;IT;LI;NL;SE)
INVENTOR:
Gotschlich, Emil Claus, 500 East 63rd Street, New York, NY 10021, (US)
Blake, Milan Scott, 500 East 63rd Street, New York, NY 10021, (US)
Wetzler, Lee Mark, 500 East 63rd Street, New York, NY 10021, (US)
Koomey, John Michael, 238 East 81st Street, New York, NY 10028, (US)
LEGAL REPRESENTATIVE:
VOSSIUS & PARTNER (100311), Postfach 86 07 67, D-81634 Munchen, (DE)
PATENT (CC, No, Kind, Date): EP 351604 A1 900124 (Basic)
EP 351604 B1 940914
APPLICATION (CC, No, Date): EP 89111832 890629;
PRIORITY (CC, No, Date): US 212786 880629
DESIGNATED STATES: BE; CH; DE; FR; GB; IT; LI; NL; SE
INTERNATIONAL PATENT CLASS (V7): C12N-015/31; A61K-039/095;
ABSTRACT EP 351604 A1
This invention relates to mutants of Neisseria useful for vaccine preparation. Specifically this invention relates to mutants of Neisseria containing mutations in a major outer membrane protein gene such that no immunologically functional polypeptides encoded by said gene are produced. More specifically, the invention relates to a mutant strain of Neisseria gonorrhoeae or Neisseria meningitidis having a mutation of the PIII gene or Class 4 gene respectively and to vaccines derived therefrom.

ABSTRACT WORD COUNT: 76

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPBBF1	638
CLAIMS B	(English)	EPBBF1	475
CLAIMS B	(German)	EPBBF1	444
CLAIMS B	(French)	EPBBF1	537
SPEC A	(English)	EPBBF1	7615

SPEC B	(English)	EPBBF1	7889
Total word count - document A			8253
Total word count - document B			9345
Total word count - documents A + B			17598

7/3,AB/37 (Item 26 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00260813
Gonococcal and meningococcal polypeptides, vaccines and diagnostics.
Gonokokken- und Meningokokken-Polypeptide, Impfstoffe und Diagnostiken.
Polypeptides des gonocoques et des meningocoques, vaccins et tests.
PATENT ASSIGNEE:
Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., (210790), Bunsenstrasse 10, D-3400 Gottingen, (DE), (applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)
INVENTOR:
Meyer, Thomas F., Vochtingstrasse 1, D-7400 Tubingen, (DE)
Stern, Anne, Karwendelstrasse 10, D-8122 Penzberg, (DE)
LEGAL REPRESENTATIVE:
Vossius & Partner , Siebertstrasse 4 P.O. Box 86 07 67, D-8000 Munchen 86 , (DE)
PATENT (CC, No, Kind, Date): EP 273116 A2 880706 (Basic)
EP 273116 A3 900502
APPLICATION (CC, No, Date): EP 87114513 871005;
PRIORITY (CC, No, Date): EP 86113993 861009
DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS (V7): C07K-007/06; C07K-007/08; C07K-007/10; C07K-015/14; G01N-033/569; G01N-033/571; A61K-039/095; A61K-039/40; C12N-015/00; A61K-037/02;

ABSTRACT EP 273116 A2
The subject matter of the invention is a polypeptide which includes an amino acid residue sequence constituted by at least 5 and up to about 80 amino acid residues, and which is capable of immunologically mimicking a conserved antigenic determinant site of a conococcal opacity protein (Protein II) and/or meningococcal class 5 protein.
The polypeptide of the invention can be used as a vaccine or diagnostic for the prevention of gonorrhea and/or meningitidis.
ABSTRACT WORD COUNT: 77

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	EPABF1	985
SPEC A	(English)	EPABF1	3192
Total word count - document A			4177
Total word count - document B			0
Total word count - documents A + B			4177

7/3,AB/38 (Item 27 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00221611
Monoclonal antibodies binding determinants of gram negative bacteria.
Monoklonale Antikorper, die Determinanten gram-negativer Bakterien binden.

Anticorps monoclonaux se liant aux determinants de bacteries gram-negatives.
PATENT ASSIGNEE:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, (221076), 2199 Addison Street, Berkeley, California 94720, (US), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
Young, Lowell S., 2025 Jackson Street, San Francisco California 94109, (US)
ALAM, Susan, 4355 N. Sepulveda, Apt 108, Sherman Oaks, CA 94103, (US)
LEGAL REPRESENTATIVE:
Harrison, David Christopher et al (31531), MEWBURN ELLIS & CO 2/3 Cursitor Street, London EC4A 1BQ, (GB)
PATENT (CC, No, Kind, Date): EP 217527 A2 870408 (Basic)
EP 217527 A3 890208
EP 217527 B1 921007
APPLICATION (CC, No, Date): EP 86306420 860819;
PRIORITY (CC, No, Date): US 781242 850927; US 855878 860424
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS (V7): C12P-021/00; C07K-015/00; C12N-005/00; G01N-033/577; G01N-033/569; G01N-033/543; C12N-015/00; A61K-039/40; C12P-021/00; C12R-001/91

ABSTRACT EP 217527 A2
The present invention provides novel hybridóma cell lines which produce monoclonal antibodies (MoAbs) that bind epitopes found on lipopolysaccharide most commonly associated with the endotoxin core of gram negative bacteria and exhibit broad cross-reactivity with gram negative bacteria of different genera and effectively neutralize endotoxin. At least one of the MoAbs disclosed (XMMEN-J5D) binds an epitope also found on gram positive bacteria. The hybridomas are produced by fusing an immortal cell, a cell having the ability to replicate indefinitely in myeloma cell culture, and an effector immune cell following immunization of the immune cell host with a preparation of a gram negative bacteria. While several individual hybridoma cell lines producing monoclonal antibodies to lipopolysaccharide are described, the present invention adds to the state of the art an entire family of hybridomas producing monoclonal antibodies to lipopolysaccharide-associated epitopes.
The monoclonal antibodies produced by the hybridoma cell lines the present invention are useful in the detection of bacterial infections, therapy and prophylaxis of bacterial endotoxemia and infection caused by gram negative bacteria.
ABSTRACT WORD COUNT: 174

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	512
CLAIMS B	(German)	EPBBF1	369
CLAIMS B	(French)	EPBBF1	438
SPEC B	(English)	EPBBF1	7476
Total word count - document A			0
Total word count - document B			8795
Total word count - documents A + B			8795

7/3,AB/39 (Item 28 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

00195212
IMPROVED ANTIGENIC PREPARATION.
VERBESSERTE ANTIGENZUSAMMENSETZUNG.
PREPARATION AMELIOREE D'ANTIGENES.
PATENT ASSIGNEE:
THE COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION, (200830), Limestone Avenue, P.O. Box 1600, Canberra, Australian Capital Territory 2601, (AU), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
THE UNIVERSITY OF SYDNEY, (221921), Parramatta Road, Sydney, New South Wales 2006, (AU), (applicant designated states: AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)
INVENTOR:
MATTICK, John, Stanley, 57 Essex Street, Epping, NSW 2121, (AU)
ANDERSON, Belinda, Jane, 102a Glassop Street, Balmain, NSW 2041, (AU)
ELLEMAN, Thomas, Charles, 12 Swan Avenue, Westmeadows, VIC 3049, (AU)
LEGAL REPRESENTATIVE:
Mair, Richard Douglas et al (50251), F.J. Cleveland & Company 40-43 Chancery Lane, London WC2A 1JQ, (GB)
PATENT (CC, No, Kind, Date): EP 202260 A1 861126 (Basic)
EP 202260 A1 880511
EP 202260 B1 920603
WO 8602557 860509
APPLICATION (CC, No, Date): EP 85905494 851031; WO 85AU263 851031
PRIORITY (CC, No, Date): AU 847930 841031
DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
INTERNATIONAL PATENT CLASS (V7): A61K-039/02; A61K-039/095; A61K-039/104; C07K-015/04; C12N-015/31; C12P-021/00;
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	1036
CLAIMS B	(German)	EPBBF1	912
CLAIMS B	(French)	EPBBF1	1066
SPEC B	(English)	EPBBF1	8283
Total word count - document A			0
Total word count - document B			11297
Total word count - documents A + B			11297

7/3,AB/40 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0399279 DBR Accession No.: 2006-12775 PATENT
Novel bacterium having cell wall comprising peptidoglycan and knockout mutation of its mltA gene and does not express protein having lytic transglycosylase activity of MltA protein, useful for preparing vesicles for treating septicemia - for use in vesicle and recombinant vaccine preparation and septicemia and meningitis infection prevention and therapy
AUTHOR: ADU-BOBIE J; PIZZA M; NORAIS N; FERRARI G; GRANDI G
PATENT ASSIGNEE: CHIRON SRL 2006
PATENT NUMBER: WO 200646143 PATENT DATE: 20060504 WPI ACCESSION NO.: 2006-332357 (200634)
PRIORITY APPLIC. NO.: GB 200424092 APPLIC. DATE: 20041029
NATIONAL APPLIC. NO.: WO 2005IB3494 APPLIC. DATE: 20051028

LANGUAGE: English

ABSTRACT: DERWENT ABSTRACT: NOVELTY - A bacterium (I) having a cell wall that includes peptidoglycan and a knockout mutation of its mltA gene, and does not express a **protein** having the lytic transglycosylase activity of MltA **protein** , is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a **meningococcal** vesicle (II) obtainable by culturing (I); (2) a composition (C1) comprising (a) vesicles that, during culture of (I) are released into the culture medium, where the vesicles are present in the filtrate obtainable after filtration through a 0.22 microns filter of a culture medium in which (I) has been grown, or (b) a first set of (II) and a second set of (II), where the first and second sets are prepared from different strains of **meningococcus** ; and (3) a pharmaceutical composition (PC) comprising (II). WIDER DISCLOSURE - A kit comprising the vesicle, is also disclosed. BIOTECHNOLOGY - Isolation: (I) is **isolated** by standard recombinant technique. Preferred Bacterium: (I) also has a knockout mutation of one or more genes. (I) is in the Neisseria or Escherichia genus, preferably Neisseria **meningitidis** . The N. **meningitidis** is from serogroup A, B, C, W135 or Y. (I) is a gna33- lpxA- PorA- **meningococcus**. (I) is Escherichia coli, preferably a pathogenic E. coli. The pathogenic E. coli is an extraintestinal pathogenic bacterium, a uropathogenic bacterium, or meningitis/sepsis-associated bacterium. (I) is preferably a pathogenic E. coli, which is a tolR- strain and does not express a **protein** of the Tol-Pal complex. Preferred Composition: (C1) does not comprise any living and/or whole bacteria. (C1) and PC includes an adjuvant. Preferred Vesicle: (II) does not include one or more of MinD, FtsA and/or phosphoenolpyruvate synthase **proteins** . (II) is substantially free from ribosomes, any aminoacid tRNA-synthetases, or any enzyme from the Krebs cycle. (II) includes 47 **proteins** such as NMB0035, NMB0044, NMB0086, NMB0088, NMB0109, NMB0124, NMB0138, NMB0182, NMB0204, NMB0278, NMB0294, NMB0313, NMB0345, NMB0346, NMB0382, NMB0460, NMB0461, NMB0550, NMB0554, NMB0623, NMB0634, NMB0663, NMB0703, NMB0787, NMB0873, NMB0928, NMB1030, NMB1053, NMB1057, NMB1126, NMB1285, NMB1301, NMB1332, NMB1429, NMB1483, NMB1533, NMB1567, NMB1612, NMB1710, NMB1870, NMB1898, NMB1949, NMB1961, NMB1972, NMB1988, NMB2039 and NMB2091. ACTIVITY - Antibacterial; Immunostimulant; Immunosuppressive; Neuroprotective. MECHANISM OF ACTION - Vaccine. Analysis of ability of mltA-derived vesicles as a vaccine for killing a broad panel of MenB clinical **isolates** , was carried out as follows. The DeltamltA-derived vesicle (10 micrograms) and outer membrane vesicle (OMVs) (10 micrograms) (prepared by chemical extraction) was adsorbed to an aluminum hydroxide adjuvant (3 mg/ml) and injected into CD1 female mice (5-10 mice per group) (5-week old). The vesicles were given intraperitoneally on days 0 and 21. Blood samples for analysis were taken on day 34, and were tested for serum bactericidal antibodies (SBA) against 15 different serogroup B strains corresponding to 11 different sub-types, including the four major hypervirulent lineages, using pooled baby rabbit serum as the complement source. The results showed that serum bactericidal titers were resulted in 50% decrease in colony forming units/ml (CFU/ml) after 60 minutes incubation of bacteria with reaction mixture, compared to control CFU/ml at time 0. The vesicles were effective against 87% of the strains, whereas the artificial OMVs were only 40% effective. USE - (I) is useful for preparing bacterial vesicles (II), which involves culturing (I) in a culture medium such that (I) releases vesicles into the medium, and collecting the vesicle from the medium (claimed). (II) is useful in the manufacture of a medicament, e.g. vaccine for immunizing a patient. Composition (C1), PC or (II) is useful for preventing and/or treating a disease caused by N. **meningitidis** (e.g. bacterial meningitis or

septicemia. (C1) is useful for vaccine preparation. ADMINISTRATION - (C1) or PC is administered by subcutaneous, intravenous, intraperitoneal, intramuscular, rectal, oral, vaginal, topical, transdermal, intranasal, ocular or pulmonary route. No specific dosage details are given. ADVANTAGE - (I) spontaneously release vesicles that are rich in immunogenic outer membrane **proteins** and that can elicit cross-protective antibody responses with higher bactericidal titers than outer membrane vesicles by simple, efficient and less time-consuming disruption and purification methods. EXAMPLE - Production of ?mltA knockout strain and preparation of bacterial vesicles, was carried out as follows. Neisseria **meningitidis** strain MC58 was transformed with plasmid pBSUDGNA33ERM. The upstream flanking region (including the start codon) from position -867 to +75 and the downstream flanking region (including the stop codon) from position +1268 to +1744 were amplified from MC58 by using the primers U33FOR, U33REV, D33FOR and D33REV. The fragments were cloned into pBluescript and transformed into Escherichia coli DH5. The naturally competent Neisseria strain MC58 was transformed by selecting a few colonies grown overnight on GC agar plates and mixing them with 10 mM Tris-hydrochloric acid (20 mul, pH 6.5) containing plasmid DNA (1 micrograms). The mixture was spotted onto a chocolate agar plate, incubated for 6 hours at 37degreesC and then diluted in phosphate buffered-saline (PBS) and spread on GC agar plates containing erythromycin (7 micrograms/ml). Allelic exchange with the chromosomal mltA gene was verified by performing PCR, and lack of MltA expression was confirmed by Western blot analysis. The results showed that the ?mltA knockout strain does not have the correct topological organization of the cellular membrane, has abnormal cell separation, abnormal cell morphology, undivided septa, double septa, cell clustering, sharing of outer membranes and reduced virulence. The ?mltA-derived vesicles were compared to **meningococcal** vesicles prepared by the normal detergent extraction method. **Meningococcal** strains MC58, NZ394/98 and NZ98/254, and their respective isogenic ?mltA mutants, were grown in 20 ml or 200 ml GC culture medium in humidified atmosphere containing 5% carbon-dioxide. Bacteria were collected by centrifugation for 10 minutes. Vesicles (DOMVs) were prepared from the wild-type bacteria by detergent extraction. Vesicles (mOMVs) were prepared from knockout strains by filtration through a 0.22 microns pore size filter, followed by high-speed centrifugation of the filtrates, washing of the vesicle-containing pellets twice with PBS, and then re-suspension with PBS. Both the mOMVs and DOMVs were analyzed by denaturing mono-dimensional electrophoresis. The vesicle **proteins** (20 micrograms) were resolved by **sodium dodecyl** sulfate-polyacrylamide **gel electrophoresis** (**SDS-PAGE**) and visualized by Coomassie Blue staining. The amount of **protein** was determined by DC **protein** assay using bovine serum albumin as a standard **protein**. The yield of vesicles in a growing culture was also assessed. The results showed that 20 mg of OMV-associated **proteins** could be **recovered** per g of cells in culture supernatants of early exponentially growing cultures. The MC58 ?mltA mutant-derived vesicles had 65 **proteins**, in which 61 **proteins** were membrane-associated **proteins**.(56 pages)

7/3,AB/41 (Item 2 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0353872 DBR Accession Number: 2004-26164 PATENT
New DNA comprising a gene sequence encoding lysine decarboxylase and a

signal secretion sequence for encoding a cell surface location protein, for producing an expression vector used to transform yeast to produce cadaverine - recombinant enzyme production via plasmid expression in host cell for use in cadaverine production

PATENT ASSIGNEE: TORAY IND INC 2004

PATENT NUMBER: JP 2004298034 PATENT DATE: 20041028 WPI ACCESSION NO.: 2004-760830 (200475)

PRIORITY APPLIC. NO.: JP 200393157 APPLIC. DATE: 20030331

NATIONAL APPLIC. NO.: JP 200393157 APPLIC. DATE: 20030331

LANGUAGE: Japanese

ABSTRACT: DERWENT ABSTRACT: NOVELTY - A DNA (I) that express lysine decarboxylase on the surface of a cell, comprising a structural gene sequence for encoding lysine decarboxylase and a portion of a signal secretion sequence for encoding a cell surface location **protein**, is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) an expression vector (II) comprising (I); and (2) yeast (III) comprising (II). BIOTECHNOLOGY - Preferred DNA: The structural gene sequence of (I) is derived from a microorganism e.g., bacteria. The structural gene of lysine decarboxylase A is obtained from Bacillus halodurans, B. subtilis, Escherichia coli, Selenomonas ruminantium, Vibrio cholerae, V. parahaemolyticus, Streptomyces coelicolor, S. pilosus, Eikenella corrodens, Eubacterium acidaminophilum, Salmonella typhimurium, Hafnia alvei, Neisseria **meningitidis**, Thermoplasma acidophilum or Pyrococcus abyssi (preferably E. coli). The signal secretion sequence encodes amino acids from position 1099 of Flo1 **protein** (cohesion **protein**) of a budding yeast e.g., Saccharomyces cerevisiae. Preferred Vector: (II) Is utilized as a plasmid for stably maintaining the chromosome of yeast cell. Preferred Yeast: (III) Is Saccharomyces cerevisiae. USE - (III) Is useful for producing cadaverine which involves contacting (III) and aqueous solution that contains lysine e.g., L-lysine, in the presence of pyridoxal phosphoric acid (claimed). (I) Is useful for producing (II) utilized for transforming yeast to produce cadaverine. ADVANTAGE - (I) Enables efficient production of cadaverine. EXAMPLE - To produce DNA that encodes lysine decarboxylase, lysine decarboxylase gene e.g., cadA was **isolated** from Escherichia coli DH5alpha strain. The gene was amplified by a sequence of gcagatctaacgttattgcaatattgat and gcgtcgacttatttttgctttcttctttcaata. The amplified product was inserted into BglII and XhoI site of pWIFS plasmid, to produce pHS39 vector. The vector was transduced into Saccharomyces cerevisiae. The transformed organism was cultured in a suitable medium that was devoid of tryptophan. The cultured cells were crushed in the presence of tris-buffered saline (TBS) buffer. The supernatant liquid was utilized for extracting the soluble **protein**. The precipitate was utilized as the cell wall fraction. The fractions were **isolated** by **Sodium dodecyl** sulfate-polyacrylamide **gel electrophoresis (SDS-PAGE)**. The supernatant and cell wall fraction were subjected to Western blotting. The result showed the presence of lysine decarboxylase only from the cell wall fraction. (19 pages)

7/3,AB/42 (Item 3 from file: 357)

DIALOG(R)File 357:Derwent Biotech Res.

0307226 DBR Accession Number: 2003-09011 PATENT

Novel immunogenic mutant cholera holotoxin for preparing immunogenic composition for enhancing immune response of vertebrate host to bacterial or viral antigen, has reduced toxicity compared to wild-type

cholera toxin - vector-mediated gene transfer and expression in host cell for recombinant vaccine and immunostimulant
AUTHOR: GREEN B A; HOLMES R K; JOBLING M G; ZHU D
PATENT ASSIGNEE: AMERICAN CYANAMID CO; UNIV COLORADO 2002
PATENT NUMBER: WO 200298368 PATENT DATE: 20021212 WPI ACCESSION NO.: 2003-140542 (200313)
PRIORITY APPLIC. NO.: US 296537 APPLIC. DATE: 20010607
NATIONAL APPLIC. NO.: WO 2002US20978 APPLIC. DATE: 20020605
LANGUAGE: English
ABSTRACT: DERWENT ABSTRACT: NOVELTY - An immunogenic, mutant cholera holotoxin (CT-CRM) (I) comprising an amino acid sequence of subunit A of the wild-type cholera toxin (CT), where the subunit A comprises an amino acid substitution in the wild-type CT subunit A amino acid position 16 or 72, and the mutant CT-CRM has reduced toxicity compared to the wild-type CT, is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) an immunogenic composition (C) comprising (I) which enhances the immune response in a vertebrate host to an antigen; (2) an **isolated** an purified DNA sequence (II) encoding (I); (3) a nucleic acid molecule (III) comprising an **isolated** and purified nucleic acid sequence encoding (I) and where the sequence encoding (I) is operatively linked to regulatory sequences enabling expression of (I) in a host cell; (4) a host cell transformed, transduced, infected or transfected with (III); and (5) producing (I). WIDER DISCLOSURE - (1) a plasmid containing **isolated** and purified DNA sequence comprising a DNA sequence encoding (I); (2) a host cell line transformed, infected, transduced or transfected with the plasmid of (1); (3) nucleic acid fragments encoding (I); and (4) an **isolated** nucleotide molecule comprising a nucleic acid sequence that is at least 70, 80 or 90 % homologous to a nucleic acid sequence encoding (I). BIOTECHNOLOGY - Preparation: (I) is prepared by transforming, infecting, transducing or transfecting a host cell with (III) and culturing the host cell under conditions which permit the expression of recombinant immunogenic detoxified **protein** by the host cell (claimed). Preferred Holotoxin: (I) comprises a single amino acid substitution located at amino acid position 16, preferably isoleucine in the amino acid position 16 in the A subunit is substituted with an alanine. The subunit A differs from the wild-type CT by an amino acid substitution located at amino acid position 16 and an amino acid substitution located at position 68. The amino acid isoleucine in the amino acid position 16 is substituted with alanine and the serine in position 68 is substituted with alanine. (I) comprises a single amino acid substitution located at amino acid position 72. Valine in the amino acid position 72 in the A subunit is substituted with a tyrosine. The subunit A differs from the wild-type CT by an amino acid substitution located at amino acid position 72 and 68. The amino acid serine in the amino acid position 68 in the A subunit is substitute with an alanine, and valine in the amino acid position 72 is substituted with tyrosine. (I) further comprises an additional mutation in the A subunit of the cholera holotoxin at an amino acid position other than the amino acid positions 16, 68 and 72 in the A subunit. The additional mutation is arginine, aspartic acid, arginine, glutamic acid, histidine, valine, arginine, serine, serine, histidine, valine, tyrosine, proline, histidine, serine, glutamic acid, glutamic acid, serine, tryptophan, arginine or arginine, at amino acid position 7, 9, 11, 29, 44, 53, 54, 61, 63, 70, 97, 104, 106, 107, 109, 110, 112, 114, 127, 146, or 192, respectively. (I) further comprises an antigen derived from pathogenic bacterium, virus, fungus or parasite, cancer cell, tumor cell, allergen or a self-molecule. In (C), the bacterial, fungal, parasite or viral antigen is a **protein**, **polypeptide**, **peptide** or a fragment derived from a

protein . (C) further comprises a diluent, excipient or carrier and a second adjuvant in addition to (I). In (III), the regulatory sequence is an inducible promoter (arabinose inducible promoter). The molecule is a viral or non-viral vector. The non-viral vector is a DNA plasmid. ACTIVITY - Immunosuppressive; Nootropic; Neuroprotective; Cytostatic; Antibacterial; Virucide; Antiparasitic; Fungicide. No biological data is given. MECHANISM OF ACTION - Immune response enhancer (claimed). Immune response of Balb/c mice immunized with recombinant P4 outer membrane **protein** (RP4) of non-typable Haemophilus influenzae (NTHI) alone or in conjunction with (I), was investigated. The ability of mutant CT-CRMI16A to enhance the induction of systemic and mucosal antibodies to recombinant P4 outer membrane **protein** , (rP4) were then assessed. Serum and mucosal anti-P4 antibody titers induced by mutant CT-CRMI16A, were assessed and compared with that of wild-type CT and mutant CT-CRME29G. Balb/c mice were immunized intranasally (IN) at weeks 0, 3 and 5 and at week 5, day 6 with a formulation containing 1 micro-g of recombinant P4 **protein** in saline or 1 micro-g of P4 together with 1 micro-g of wild-type CT, 1 micro-g of CT-CRME29H or 0.1 or 10 micro-g of CT-CRMI16A. The result indicated that the CT-CRMI16A, like that wild-type CT and CT-CRME29H, augmented the capacity of rP4 **protein** to elicit systemic and mucosal immune responses. Six weeks after primary IN immunization the anti-rP4 IgG antibody titers of mice immunized with rP4 **protein** formulated with either CT-CRMI16A or CT-CRME29H were 40 times greater than that of mice immunized with the recombinant **proteins** in phosphate buffered saline (PBS) alone. The antibody titers (IgG) of mice administered the recombinant **proteins** plus wild-type CT holotoxin at a concentration of 1 micro-g were elevated 67-fold in comparison to antibody titers in mice administered recombinant rP4 alone in saline. The antibody titers of mice immunized with 1 micro-g of the mutant CT-CRM, CT-CRME29H were elevated 55-fold over antibody titers in mice immunized with rP4 alone. In comparison, the antibody titers of mice immunized with 1 micro-g and 0.1 micro-g of the mutant CT-CRM, CT-CRMI16A, were increased 15-fold and 27-fold, respectively over the anti-rP4 antibody titers in mice immunized with rP4 alone in saline. USE - (C) is useful for enhancing the immune response of a vertebrate host to an antigen. (I) in combination with antigen from a pathogenic bacterium, virus, fungus, parasite, a cancer cell, a tumor cell and allergen, a self molecule, or vertebrate antigen, for preparing an immunogenic composition and thus enhances the immune response in a vertebrate host to the antigen. The bacterial antigen is from any one of the 35 bacterial species given in the specification, e.g. typable and non-typable Haemophilus influenzae, H. somnus, Moraxella catarrhalis, Streptococcus pneumoniae. The H. influenzae antigen is selected from H. influenzae P4 or P6 outer membrane **protein**, and H. influenzae adherence and penetration **protein** (Haps). The Helicobacter pyloriantigen is Helicobacter pylori urease **protein**. The Neisseria **meningitidis** antigen is selected from N. **meningitidis** Group B recombinant class I pilin (rpilin) and the N. **meningitidis** Group B class 1 outer membrane **protein** (P or A). The viral antigen is from any one of the 36 viral species given in the specification e.g. respiratory syncytial virus, herpes simplex virus (HSV), Hepatitis B virus. The respiratory syncytial virus antigen is the respiratory syncytial virus fusion **protein**. The HSV antigen is HSV type 2 **glycoprotein** D (gD2). The fungal antigen is from a fungus such as Aspergillis, Blastomyces, Candida, Coccidiodes, Cryptococcus or Histoplasma. The parasite antigen is from a parasite such as Leishmania major, Ascaris, Trichuris, Giardia, Schistosoma, Cryptosporidium, Trichomonas, Toxoplasma gondii or Pneumocystic carinii. The cancer or tumor cell

antigen is a prostate specific antigen, carcino-embryonic antigen, MUC-1, Her2, CA-125, MAGE-3, hormone or a hormone analogs. The antigen is a **polypeptide**, **peptide** or a fragment derived from amyloid precursor **protein**, or an allergen. The amyloid precursor **protein** antigen is an Abeta **peptide**, which is a 42 amino acid fragment of amyloid precursor **protein**, or a fragment of Abeta **peptide**. (II) is useful for producing (I), and in in vivo production of (I) in a cell. (All claimed.) (I) is useful as a adjuvant in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, cancer cell, tumor cell, allergen, or self molecule. (I) is useful for the prevention and/or treatment of diseases caused by pathogenic bacteria, virus, fungus or parasite and non-infection diseases such as allergy, autoimmune disease, Alzheimer's disease and cancer, for eliciting a therapeutic or prophylactic anti-cancer effect, for moderating response to allergens in a vertebrate host, for preventing or treating disease characterized by amyloid deposition in a vertebrate host. ADMINISTRATION - (I) is administered at a dose of 1 micro-g-20 mg/ml, or nucleic acid encoding (I) is administered at a dose of 50 micro-g-1 mg, through intranasal, oral, vaginal, rectal, parenteral, intradermal, transdermal, intramuscular, intraperitoneal, subcutaneous, intravenous or intraarterial route. ADVANTAGE - (I) has reduced toxicity compared to wild-type cholera holotoxin (claimed). EXAMPLE - Immunogenic, mutant cholera holotoxin (CT-CRM) mutant, CT-CRMI16A mutant was made directly in pMGJI42 using the Quick Change mutagenesis kit. The double mutant plasmid containing the CT-CRMS68Y, V72Y substitutions was made by polymerase chain reaction (PCR) using the mutagenic primer such as CCTCCTGATGAAGSYCAAGCAGTCAGG (I16A), GTTTGAGATCTGCCCACT (S68Y), GTTTGACCCACTAAGTGGGC (V72Y), GTTTGAGATATGCCCACTTATATGGTCAAC (S68Y+V72Y), to create a megaprimer followed by cloning of the mutated ctxA-encoding XbaI-claI fragment into pMGJ142. The CT-CRMI16A,S68Y double mutant was made by PCR of the I16a containing clone using the mutagenic primer to create a megaprimer followed by cloning of the mutated ctxA-encoding XbaI-claI fragment into pMGJ142. The CT-CRMV72Y and CT-CRMI16A,S68Y mutants were made by reversion of the CT-CRMS68Y,V72Y double mutant back to wild-type at amino acid position 68 using the QuickChange mutagenesis it. Each single-stranded oligonucleotide was phosphorylated and used to direct second strand synthesis on a uracil-containing single-stranded DNA template rescued from the Escherichia coli dut ung strain CJ236 (F'Tc, pMGJ67). Following ligation and transformation of jung+ strain TX1, single-stranded DNA was rescued from AmpR transformants and sequenced. Arabinose promoted CT-CRM expression vectors were then constructed. CT-CRM was expressed in E. coli, and then purified. Native polyacrylamide **gel electrophoresis** (PAGE) indicated the presence of a purified molecule of 86 kDa which was the expected molecular weight for intact cholera holotoxin. In addition, sodium dodecyl sulfate (SDS)-PAGE showed two bands that aligned with the CT-A (27 kDa) and CT-B (12 kDa) subunits that comprised the intact holotoxin. (89 pages)

? log y
22sep06 10:40:53 User219783 Session D2226.3

```
 22sep06 14:53:48 User219783 Session D2227.2

SYSTEM:OS  - DIALOG OneSearch
  File  65:Inside Conferences 1993-2006/Sep 22
        (c) 2006 BLDSC all rts. reserv.
  File 266:FEDRIP 2006/Aug
        Comp & dist by NTIS, Intl Copyright All Rights Res
  File 440:Current Contents Search(R) 1990-2006/Sep 22
        (c) 2006 The Thomson Corp
  File 348:EUROPEAN PATENTS 1978-2006/ 200638
        (c) 2006 European Patent Office
*File 348: For important information about IPCR/8 and forthcoming
changes to the IC= index, see HELP NEWSIPCR.
  File 357:Derwent Biotech Res. _1982-2006/Sep W3
        (c) 2006 The Thomson Corp.
  File 113:European R&D Database 1997
        (c)1997 Reed-Elsevier(UK)Ltd All rts reserv
*File 113: This file is closed (no updates)

      Set  Items  Description
      ---  -----  -----------

Set     Items   Description
S1       9032   AU=(JACKSON, J? OR JACKSON J? OR JACKSON W? OR JACKSON, W?)
S2       5512   AU=(HARRIS, A? OR HARRIS A?)
S3         39   S1 AND S2
S4      14505   S1 OR S2
S5         10   (S3 OR S4) AND ((MENINGITID? OR MENINGOCOCC?)(S)(PROTEIN? ?
               OR POLYPROTEIN? ? OR PEPTIDE? ? OR POLYPEPTIDE? ?))
S6         10   RD  (unique items)
>>>No matching display code(s) found in file(s): 65, 113

 6/3,AB/1     (Item 1 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2006 The Thomson Corp. All rts. reserv.

21814341  Document Delivery Available: 0002323674
PUBLICATION:       JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2005
ISSN: 0021-972X


 6/3,AB/2     (Item 2 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2006 The Thomson Corp. All rts. reserv.

18684539  Document Delivery Available: 0002220158
PUBLICATION:       JOURNAL OF CLINICAL MICROBIOLOGY, 2004
ISSN: 0095-1137


 6/3,AB/3     (Item 3 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2006 The Thomson Corp. All rts. reserv.

09237701
PUBLICATION:       JOURNAL OF INFECTIOUS DISEASES, 1998
ISSN: 0022-1899


 6/3,AB/4     (Item 4 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
```

- Author(s)

07409413
PUBLICATION: BIOCHEMICAL JOURNAL, 1996
ISSN: 0264-6021

6/3,AB/5 (Item 5 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

07362146
PUBLICATION: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996
ISSN: 0098-7484

6/3,AB/6 (Item 6 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

05000328
PUBLICATION: PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993
ISSN: 0891-3668

6/3,AB/7 (Item 7 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

02987882
PUBLICATION: JOURNAL OF INFECTIOUS DISEASES, 1991

6/3,AB/8 (Item 8 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)

02940459
PUBLICATION: AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1991

6/3,AB/9 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS

01145030
NEISSERIA **MENINGITIDIS** **POLYPEPTIDE**, NUCLEIC ACID SEQUENCE AND USES THEREOF
NEISSERIA MENINGITIDIS-POLYPEPTID, NUKLEINSAURESEQUENZ UND VERWENDUNGEN DAVON
POLYPEPTIDE NEISSERIA **MENINGITIDIS**, SEQUENCE D'ACIDE NUCLEIQUE ET UTILISATIONS ASSOCIEES
PATENT ASSIGNEE:
Antex Biologics, Inc., (1525991), 300 Professional Drive, Gaithersburg, MD 20879, (US), (Applicant designated States: all)
INVENTOR:
JACKSON, W., James, 1687 Armistic Way, Marriotsville, MD 21104, (US)
HARRIS, Andrea, M., Apartment 112, 120 Alessandra Court, Frederick, MD 21702, (US)

LEGAL REPRESENTATIVE:
Chapman, Paul Gilmour et al (94211), Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE, (GB)
PATENT (CC, No, Kind, Date): EP 1109454 A2 010627 (Basic)
WO 200012535 000309
APPLICATION (CC, No, Date): EP 99945257 990901; WO 99US19663 990901
PRIORITY (CC, No, Date): US 98685 P 980901
DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI
INTERNATIONAL PATENT CLASS (V7): A01N-063/00; A01N-065/00; A01N-043/04; C12N-015/00; C12N-015/09; C12N-015/70; C12N-015/74; C12N-001/12; C12N-001/20; C12N-015/63; C12Q-001/68; C12Q-001/70; G01N-033/53; C12P-021/06; C12P-021/04; A61K-039/095; A61K-039/02; A61K-051/00; A61K-039/38; A61K-038/00
NOTE:
No A-document published by EPO
LANGUAGE (Publication,Procedural,Application): English; English; English

6/3,AB/10 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0252760 DBR Accession No.: 2000-07250 PATENT
Neisseria **meningitidis** NMASP **polypeptide**, nucleotide sequences and antibodies, useful in vaccines against infection - method is used to induce an immune response to Neisseria **meningitidis** and Neisseria **meningitidis** NMASP **polypeptide** and a NMASP-derived **polypeptide** in animals
AUTHOR: **Jackson W J**; **Harris A M**
CORPORATE SOURCE: Gaithersburg, MD, USA
PATENT ASSIGNEE: Antex-Biologics 2000
PATENT NUMBER: WO 200012535 PATENT DATE: 20000309 WPI ACCESSION NO.: 2000-256581 (2022)
PRIORITY APPLIC. NO.: US 98685 APPLIC. DATE: 19980901
NATIONAL APPLIC. NO.: WO 99US19663 APPLIC. DATE: 19990901
LANGUAGE: English
ABSTRACT: Neisseria **meningitidis** NMASP **protein** of mol.weight 40,000-55,000 (SDS-PAGE) is claimed. Also claimed are: a **peptide** fragment of NMASP; an isolated antibody that binds NMASP; an antigenic composition (comprises one or more adjuvants) comprising NMASP; an isolated DNA comprising a nucleotide sequence encoding NMASP; an isolated DNA sequence having a 153 base pair sequence; an isolated DNA which comprises a nucleotide sequence that hybridizes to a disclosed sequence; plasmid pNmAH116 obtainable from Escherichia coli; a method (A) for assaying for an agent that interacts with NMASP; an antagonist which inhibits the activity of NMASP; and a method for identifying a compound which interacts with and inhibitor or activate of NMASP. NMASP can be used in a method to produce an immune response in an animal. The sequence and antibody are useful for protection against N. **meningitidis** , also may be used as ligands to detect antibodies elicited in response to N. **meningitidis** infection. Antibody generated against the NMASP **polypeptide** in an animal host will exhibit bactericidal or opsonic activity against many N. **meningitidis** strains. (75pp)
? log y
22sep06 14:56:09 User219783 Session D2227.3

```
? show files; ds
File  65:Inside Conferences 1993-2006/Sep 22
         (c) 2006 BLDSC all rts. reserv.
File 266:FEDRIP 2006/Aug
         Comp & dist by NTIS, Intl Copyright All Rights Res
File 440:Current Contents Search(R) 1990-2006/Sep 22
         (c) 2006 The Thomson Corp
File 348:EUROPEAN PATENTS 1978-2006/ 200638
         (c) 2006 European Patent Office
File 357:Derwent Biotech Res. _1982-2006/Sep W3
         (c) 2006 The Thomson Corp.
File 113:European R&D Database 1997
         (c)1997 Reed-Elsevier(UK)Ltd All rts reserv

Set     Items   Description
S1      19966   ((NA OR SODIUM)(W)DODECYL OR SDS)(5W)(PAGE OR (POLYACRYL? -
             OR POLY(W)ACRYL))(3W)ELECTROPHOR?
S2      82000   GEL(W)ELECTROPHOR?
S3         81   ((MENINGITID? OR MENINGOCOCC?)(S)(POLYPROTEIN? ? OR PROTEI-
             N? ?OR PEPTIDE? ? OR POLYPEPTIDE? ?))(S)(ISOLATING OR ISOLATE?
              ? OR ISOL?? OR RECOVER?)
S4         12   (S1 OR S2) AND S3
S5        493   ((MENINGITID? OR MENINGOCOCC?)(S)(POLYPROTEIN? ? OR PROTEI-
             N? ? OR PEPTIDE? ? OR POLYPEPTIDE? ?))(S)(ISOLATING OR ISOLAT-
             E? ? OR ISOL?? OR RECOVER?)
S6         43   (S1 OR S2) AND S5
S7         42   RD  (unique items)
```

```
? show files; ds
File  65:Inside Conferences 1993-2006/Sep 22
         (c) 2006 BLDSC all rts. reserv.
File 266:FEDRIP 2006/Aug
         Comp & dist by NTIS, Intl Copyright All Rights Res
File 440:Current Contents Search(R) 1990-2006/Sep 22
         (c) 2006 The Thomson Corp
File 348:EUROPEAN PATENTS 1978-2006/ 200638
         (c) 2006 European Patent Office
File 357:Derwent Biotech Res. _1982-2006/Sep W3
         (c) 2006 The Thomson Corp.
File 113:European R&D Database 1997
         (c)1997 Reed-Elsevier(UK)Ltd All rts reserv

Set     Items   Description
S1       9032   AU=(JACKSON, J? OR JACKSON J? OR JACKSON W? OR JACKSON, W?)
S2       5512   AU=(HARRIS, A? OR HARRIS A?)
S3         39   S1 AND S2
S4      14505   S1 OR S2
S5         10   (S3 OR S4) AND ((MENINGITID? OR MENINGOCOCC?)(S)(PROTEIN? ?
              OR POLYPROTEIN? ? OR PEPTIDE? ? OR POLYPEPTIDE? ?))
S6         10   RD  (unique items)
```

This Page Blank (uspto)